ESC European Society of Cardiology

European Heart Journal - Cardiovascular Imaging (2024) **00**, 1–24
https://doi.org/10.1093/ehjci/jeae165

EACVI DOCUMENT

Multimodality imaging for the evaluation and management of patients with long-term (durable) left ventricular assist devices

A clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology

Matteo Cameli [1]*†, Hatem Soliman Aboumarie[2,3]†, Maria Concetta Pastore[1], Kadir Caliskan[4], Maja Cikes[5], Madalina Garbi[6], Hoong Sern Lim[7], Denisa Muraru[8,9], Giulia Elena Mandoli[1], Valeria Pergola [10], Sven Plein [11], Gianluca Pontone [12], Osama I. Soliman[13], Pal Maurovich-Horvat[14], Erwan Donal [15], Bernard Cosyns[16,17], and Steffen E. Petersen[18,19]

Reviewers: This document was reviewed by members of the 2022–2024 EACVI Scientific Documents Committee: Alexios Antonopoulos, Yohann Bohbot, Marc Dweck, Pankaj Garg, Alessia Gimelli, Ivan Stankovic, and Valtteri Uusitalo

[1]Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, 53100 Siena, Italy; [2]Department of Anaesthetics, Critical Care and Mechanical Circulatory Support, Harefield Hospital, Royal Brompton and Harefield Hospitals, London, UK; [3]School of Cardiovascular, Metabolic Sciences and Medicine, King's College, WC2R 2LS London, UK; [4]Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; [5]Department of Cardiovascular Diseases, University Hospital Centre, Zagreb, Croatia; [6]Cardiology, Royal Papworth Hospital, Cambridge, UK; [7]Institute of Cardiovascular Sciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; [8]Department of Cardiology, Istituto Auxologico Italiano IRCCS, Milan, Italy; [9]Department of Medicine and Surgery, University Milano-Bicocca, Milan, Italy; [10]Department of Cardiology, Padua University Hospital, Padua 35128, Italy; [11]Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; [12]Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy; [13]Department of Cardiology, College of Medicine, Nursing and Health Sciences, National University of Galway, Galway, Ireland; [14]Department of Medical Imaging, Semmelweis University, Budapest, Hungary; [15]University of Rennes, CHU Rennes, INSERM, LTSI—UMR 1099, Rennes F-35000, France; [16]Centrum Voor Harten Vaatziekten (CHVZ), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium; [17]In Vivo Cellular and Molecular Imaging (ICMI) Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium; [18]William Harvey Research Institute, National Institute for Health and Care Research Barts Biomedical Research Centre, Queen Mary University London, London, UK; and [19]Barts Heart Centre, St Bartholomew's Hospital, Barts Health National Health Service Trust, London, UK

Received 12 June 2024; accepted 12 June 2024; online publish-ahead-of-print 5 July 2024

Left ventricular assist devices (LVADs) are gaining increasing importance as therapeutic strategy in advanced heart failure (HF), not only as bridge to recovery or to transplant but also as destination therapy. Even though long-term LVADs are considered a precious resource to expand the treatment options and improve clinical outcome of these patients, these are limited by peri-operative and post-operative complications, such as device-related infections, haemocompatibility-related events, device mis-positioning, and right ventricular failure. For this reason, a precise pre-operative, peri-operative, and post-operative evaluation of these patients is crucial for the selection of LVAD candidates and the management LVAD recipients. The use of different imaging modalities offers important information to complete the study of patients with LVADs in each phase of their assessment, with peculiar advantages/disadvantages, ideal application, and reference parameters for each modality. This clinical consensus statement sought to guide the use of multimodality imaging for the evaluation of patients with advanced HF undergoing LVAD implantation.

* Corresponding author. E-mail: matteo.cameli@unisi.it
† These authors are joint first authors.

Graphical Abstract



Use of multimodality imaging for pre-operative, peri-operative, and post-operative evaluation of patients with left ventricular assist devices. AR, aortic regurgitation; AV, aortic valve; CT, computed tomography; CMR, cardiac magnetic resonance; LV, left ventricular; LVAD, left ventricular assist device; PET, positron emission tomography; PFO, patent foramen ovale; RV, right ventricular; TOE, transoesophageal echocardiography; TR, tricuspid regurgitation; TTE, transthoracic echocardiography.

Keywords left ventricular assist device • heart failure • cardiac imaging • echocardiography • cardiac magnetic resonance • computed tomography

Introduction

Mechanical circulatory support (MCS) is a major breakthrough in heart failure (HF) management. Left ventricular assist devices (LVADs) may be considered in patients with advanced HF already on optimal medical and device therapy, with reduced functional capacity and frequent hospitalizations. Also, dependence on inotropic therapy or short-term MCS and progressive end-organ dysfunction are potential indications. Of note, no absolute contraindications should be present, such as right ventricular (RV) dysfunction, contraindications to oral anticoagulation, and absence of psychosocial support.

MCS devices continue to evolve with advances in technology. Long-term (durable) LVAD is a form of MCS that has undergone considerable advances over the last two decades. Besides LVADs, total artificial hearts (TAHs) are gaining their relevance in the field, but their diffusion is still limited to highly specialized centres worldwide. By replacing both ventricles, TAHs represent a completely different MCS system from a physiological standpoint.

The high incidence of HF, with consequent expansion in the number of patients with advanced disease,[1] has led to increased use of long-term LVADs. However, these long-term (or 'durable') devices are subject to peri-operative and post-operative complications, such as device-related infections, haemocompatibility-related events, device mis-positioning, and RV failure (RVF), which may affect the long-term survival of patients.[2,3] Systematic evaluation during the pre-operative, peri-operative, and post-operative periods is therefore necessary for these patients in routine clinical practice.

In addition to clinical and haemodynamic assessments of patients with HF, non-invasive imaging plays a pivotal role in the selection of LVAD candidates, the pre- and peri-operative management, and the long-term management of patients with durable LVADs. Traditionally, echocardiography has been regarded as the preferred non-invasive technique for the assessment of LVAD recipients.[4–6] However, in the current era of multimodality imaging (MMI),[7] it is timely to review the contribution of each of the various imaging modalities to highlight their relative advantages and pitfalls, not only for LVAD implantation centres but also for primary and secondary care centres who may also encounter these patients.

This European Association of Cardiovascular Imaging (EACVI) clinical consensus statement aims to provide a comprehensive guide for the use of echocardiography and MMI in the evaluation of patients with long-term LVADs in clinical practice. This document will describe (i) the role and pitfalls of each imaging modality and (ii) the use of different

Box 1 Key points

HF epidemic is growing, resulting in an increasing demand for durable LVADs.

Non-invasive MMI plays a crucial role in the work-up of patients considered for LVAD, as well as in their peri-operative and post-operative assessment and management.

In addition to clinical and haemodynamic assessment, MMI plays a pivotal role in the selection of LVAD candidates and in the management of patients with durable LVADs.

The identification and evaluation of LVAD complications (such as thromboembolism, valvular heart disease, bleeding, device mis-positioning, and, importantly, RVF) are crucial.

The use of a systematic MMI approach is essential to ensure early recognition of LVAD complications

HF, heart failure; LVAD, left ventricular assist device; MMI, multimodality imaging; RVF, right ventricular failure.

imaging modalities to complement clinical and invasive assessments to guide patient selection and both the peri-operative and post-operative management of patients with LVADs (Box *1*).

LVADs

Different generations of LVADs

Shortage of donor organs and limited access to heart transplantation have contributed to the increased interest in LVADs for patients with end-stage left ventricular (LV) failure. The first major clinical trial of durable LVADs started in the 1990s with the first generation of pulsatile LVADs. The development of smaller second-generation continuous-flow (CF) axial LVADs led to easier device implantation as well as improved durability. The HeartMate II device was one of the most commonly used second-generation axial-flow LVADs in the 2000s.

The third-generation centrifugal pump HeartMate 3 LVAD was introduced in 2015. The HeartMate 3 LVAD has an 'artificial pulse' and several features to improve haemocompatibility. In the MOMENTUM-3 randomized trial, the centrifugal-flow HeartMate 3 device was associated with lower incidence of mortality, stroke, and pump thrombosis (PT) compared to the axial-flow HeartMate II device,[8] and a 58% 5-year survival was recently documented in the long-term follow-up of the trial cohort.

LVAD anatomy

The LVAD consists of an intrathoracic part: (i) the pump with the associated inflow cannula (in the LV apex) and the outflow graft (from the pump to the ascending aorta), and external components: (ii) the pump controller and (iii) the cables connected to a pair of external batteries or power source. Blood is drawn from the LV via the inflow cannula into the pump and delivered via the outflow graft to the ascending aorta (*Figure 1*). The outflow graft is typically positioned at the lower margin of the RV and courses along the right heart border to anastomose at the ascending aorta. In occasional cases, the outflow graft may be anastomosed to the descending aorta.

LVAD physiology

The LVAD competes with the LV for preload and provides a parallel circulation from the LV to the aorta. It continuously drains blood from the LV and deliver it to the aorta, with (i) reduction in LV size and filling pressures (commonly accompanied by improvement in functional mitral regurgitation), (ii) reduction in LV native stroke volume and work, and (iii) loss of isovolumic phases in the cardiac cycle. In general, these effects are directly related to the programmed pump speed.

The flow generated by the LVAD is preload dependent and afterload sensitive. Hypovolaemia and/or RV failure at an unchanged pump speed will lead to reduction in LV chamber volume (i.e. LV and LVAD preload), which may result in (i) reduced intrinsic LV stroke volume, stroke work, and LVAD flow; (ii) loss of aortic valve (AV) opening if the LV fails to overcome aortic pressure; and (iii) trigger 'suction events' (i.e. events where the pump speed automatically and transiently drops to a pre-set lower level). Excessive emptying of the LV may also result from inappropriately high pump speed, and this may trigger ventricular arrhythmias and compromise RV function. LVAD flows are also afterload sensitive. Therefore, increased LV afterload (raised mean arterial pressure) can compromise LVAD flows.

Considerations for imaging

Candidates to LVAD therapy may be administered with inotropic/vasopressor drugs to maintain adequate end-organ perfusion, especially if on INTERMACS Class 3 or higher. Therefore, imaging examinations in these patients should always consider the potential impact of medical therapy on findings and possibly state the specific drug and posology in the examination report. Many considerations should be taken into account when performing imaging examinations in these cases: the observed systolic function of both ventricles could be influenced leading to an overestimation of it; positive chronotropic effect and arrhythmias may potentially limit the quality of second-level examinations; and ischaemia evaluation and heart valves functioning may be unreliable in these patients as well since oxygen demand/supply and preload/afterload may vary. The same precautions should be considered also in the peri-operative period.

The objectives of LVAD therapy are as follows: (i) improving systemic cardiac output (combination of LV native stroke volume and LVAD flow); (ii) unloading the LV; and (iii) without inducing complications associated with a non-physiological parallel blood flow circuit (such as RV failure and aortic regurgitation). Imaging assessment of a patient with LVAD should exploit these anatomical and physiological concepts of heart–LVAD interaction to facilitate effective delivery of LVAD therapy. The three essential components of imaging assessment are the study of LVAD outflow (by Doppler imaging), LV unloading, and LVAD-related complications. However, MMI of LVADs currently represents a challenge for clinicians, and there are many issues, such as sub-optimal acoustic windows, artefacts, interference for Doppler imaging, magnetic resonance incompatibility, and blooming artefacts, that strongly limit the evaluation of these patients (Box *2*).

Pre-implantation: MMI in selection of LVAD candidates

Echocardiography

2D echocardiography

LV and RV dimensions and function

Pre-operative transthoracic echocardiography (TTE) is the key imaging modality for assessing LV and RV function and dimensions in the evaluation and selection of patients for LVAD implantation[9] (*Table 1*).

The first thing to evaluate is the existence of the primary indication for LVAD implantation, which is end-stage HF due to ischaemic or non-ischaemic dilated cardiomyopathy with severe LV systolic dysfunction, an LV ejection fraction (LVEF) <25%, and the presence of an appropriate space for an LVAD inflow cannula.[10]

The second key point to evaluate in the selection of LVAD candidates is RV function, another major determinant of a successful LVAD implantation.[11] Indeed, RV failure is currently considered the



Figure 1 The components of an LVAD (inflow cannula sits within the LV and is not shown here).

Box 2 LVAD flow

Contemporary LVADs are continuous-flow devices.

LVAD flow is preload dependent and afterload sensitive. Preload is dependent on volume status and right heart function, and afterload is dependent on mean arterial pressure.

LVAD flow may be interrogated by Doppler imaging of the outflow graft.

'Achilles heel' of contemporary LVAD devices. For tailored risk assessment, appropriate quantification of the RV function is therefore of paramount importance.

The echocardiographic assessment of the RV remains challenging due to technical difficulties in RV imaging, in addition to its complex geometry and function.[12] Key points in the echocardiographic assessment of RV are its structure, function, and tricuspid regurgitation (TR). The most useful parameters to evaluate are shown in Box *3*.[13–17] Importantly, RV in this situation must be as accurate as possible and requires a multiparametric approach ideally completed by cardiac magnetic resonance (CMR) in case of doubt.

Transoesophageal echocardiography: valvular heart disease, intracardiac thrombi, or shunts

Transoesophageal echocardiography (TOE) should be always performed during LVAD candidates' selection when TTE findings are inconclusive or incomplete or when a TOE is more appropriate, as for example in urgent cases or emergency scenarios. TOE provides added value for the assessment of valvular heart disease and for the exclusion of intracardiac thrombi and intracardiac shunts (*Table 2*).[18]

TOE provides a good assessment of the heart valves and can be essential for the assessment of prosthetic valve function and paravalvular regurgitation. TOE can help quantify native or prosthetic valve mitral stenosis and aortic regurgitation, quantification of which is crucial prior to LVAD implantation and which could be affected by the existence of low flow in the LV and elevated LV end-diastolic pressures. Moderate or severe mitral stenosis prevents LVAD cannula inflow, and more than mild aortic regurgitation could lead to recirculation of blood flow from the ascending aorta, reducing LVAD effectiveness.[19] In patients with HF with reduced EF (HFrEF), the mitral mean diastolic gradient does not reflect mitral stenosis severity, being lowered by the existence of both low flow and high LV pressure; consequently, inspection of the valve and calculation of effective valve orifice area are required to help elicit the diagnosis. Vena contracta measurements, with the benefit of the higher resolution of TOE, can help in the diagnosis of regurgitant lesions. Inspection of the AV and aortic root morphology can help in the

Table 1 Pre-implantation TTE checklist

Heart structure	Parameters
Left ventricle	LV dimensions (LVEDD, LVEDS, LVEDV, LVESV—3D preferred)
	LV systolic function (LVEF—3D preferred, LVGLS)
	LV diastolic function (E/A, e′ septal, e′ lateral, E/E′, LAVI, LA strain)
Left atrium	LA dimensions (LA area and volume index)
	LA function (LA strain)
Heart valves (better by TOE)	Mitral annulus dimensions, leaflet and papillary muscle geometry, and mitral regurgitation degree
	Aortic valve morphology and regurgitation degree
	Tricuspid annulus dimensions and regurgitation degree
	Prosthesis position and function, paravalvular regurgitation
Right ventricle	RV dimensions (RV basal, longitudinal, and medium diameter, RV volumes by 3D)
	RV function (TAPSE, TDI s′, RVFAC, RVSI, RV free wall strain)
Pulmonary pressure	sPAP
Other	Intracardiac thrombi
	Intracardiac shunts
	Size of ascending aorta

EDD, end-diastolic diameter, ESD, end-systolic diameter; EDV, end-diastolic volume, ESV, end-systolic volume; E′, mitral annular velocity by tissue Doppler imaging; E/A, early diastolic wave/late diastolic wave ratio by pulsed-wave Doppler; LA, left atrium; LAVI, left atrial volume index; LV, left ventricle; sPAP, systolic pulmonary artery pressure; RV, right ventricle; RVFAC, right ventricular fractional area change; RVSI, right ventricular sphericity index; TAPSE, tricuspid annular plane systolic excursion; TDI s′, systolic wave velocity by tissue Doppler imaging.

Box 3 Echocardiographic assessment of LV and RV function in LVAD candidates

LV severe dysfunction assessed by LVEF <25% is a major criterion for LVAD implantation.

The evaluation of LV geometry (to exclude the absence of space for LVAD cannula) and volume measurement is also advisable.

RV structure may be estimated by mid-cavitary diameter[13] and RV sphericity index (as the ratio of the short diameter at the mid-ventricular level to the long diameter in end-diastole, usually <0.5) in apical four-chamber view and RV/LV diameter ratio (usually >0.7).

RV function may be estimated by TAPSE, TDI-derived tricuspid lateral annular systolic velocity wave (S′), RVFAC (usually >35%), RV longitudinal strain, and RVEF quantified by 3D echocardiography.

Table 2 Pre-implantation TOE checklist

Heart structure	Parameters
Heart valves	Mitral valve morphology and regurgitation and/or stenosis degree
	Aortic valve morphology and regurgitation degree
	Tricuspid annulus dimensions and regurgitation degree
	Pulmonary regurgitation
Prosthetic valves	Prosthesis position and function, paravalvular leak
Intracardiac shunts	Exclusion of ventricular septal defects, atrial septal defects, partial anomalous vein drainage, and patent foramen ovale
Left atrial appendage thrombus	For patients with atrial fibrillation
LV apical thrombus and aneurysm (better by TTE)	Sub-optimal visualization of LV walls

LV, left ventricle; TTE, transthoracic echocardiography.

evaluation of co-existent significant aortic regurgitation, even though the possible underestimation of aortic regurgitation due to increased LV diastolic pressures should be considered. The regurgitant volume can be low because of low flow in the LV; the calculated regurgitant fraction might therefore better reflect the severity of aortic regurgitation.

Mitral regurgitation of any severity usually improves following LVAD implantation and LV unloading. On the contrary, moderate or severe TR may necessitate tricuspid repair or replacement at the time of LVAD implantation, to protect the RV. Pulmonary regurgitation can contribute to RV volume overload and consequent RV systolic dysfunction, particularly when LV unloading is unsuccessful.

Moreover, mechanical valves need to be identified (if not known) so that they can be replaced with a bioprostheses at the time of surgery in order to prevent additional risk of blood stasis and thrombosis.

TOE is also essential for exclusion of left atrial appendage thrombus in patients with atrial fibrillation. It can also help exclude LV apical thrombus and aneurysm formation, although the LV is often foreshortened on TOE with sub-optimal visualization of the LV walls.

A comprehensive assessment for intracardiac shunts is essential prior to LVAD implantation and can be performed with TOE using saline contrast, comprising exclusion of ventricular septal defects in patients with ischaemic cardiomyopathy, exclusion of atrial septal defects, partial anomalous venous drainage, and a patent foramen ovale (PFO). Flow through an atrial septal defect or PFO can reverse following LVAD implantation, causing right-to-left shunt and subsequent

arterial hypoxaemia, because of the reduction in left atrial pressure following left heart offloading. Identification and correction of an interatrial shunt are therefore essential before or during LV implantation (Box 4).[20]

Speckle tracking echocardiography

Speckle tracking echocardiography (STE) allows the analysis of myocardial deformation, i.e. 'strain' of all cardiac chambers.[21]

Box 4 TOE for pre-operative evaluation of LVAD candidates

TOE provides added value for the assessment of valvular heart disease and recognition of mechanical valves in LVAD candidates.

Calculation of mitral valve area and aortic regurgitant fraction by TOE allow a better assessment of mitral stenosis and aortic regurgitation, respectively, in patients with low flow and high LV pressure.

To investigate the presence of intracardiac shunts or masses by TOE is advisable before LVAD implantation.

STE is particularly useful for RV evaluation in patients referred for LVADs, allowing the detection of subclinical RV dysfunction that may predispose to the development of post-LVAD RV failure. Two parameters may be measured for this purpose: RV global longitudinal strain (GLS), which analyses the deformation of the whole RV wall divided into six segments, and free wall RV longitudinal strain (fwRVLS), which analyses three RV segments limited to the RV free wall. fwRVLS is considered the most accurate, as it focuses on RV physiological function in which the RV free wall contributes to 80% of RV output (*Figure 2*). By contrast, RV GLS also includes the interventricular septum (IVS), which may be influenced by LV kinetics and could therefore underestimate RV function in HFrEF patients, although it can be argued that the IVS contributes to RV systolic function, and that therefore impaired IVS function is an important component of impaired RV function.[22,23]

Both pre-operative RV GLS and fwRVLS have been found to be reduced in patients undergoing LVAD implantation who develop subsequent RVF, as confirmed in a recent meta-analysis.[24] RV strain has also demonstrated superior prognostic information to conventional echocardiographic parameters of LV and RV function in patients with chronic HF.[25,26]

Moreover, as compared to invasive techniques, fwRVLS (usually < −22%) has been shown to have good correlation with RV stroke work index, which is the most used invasive measurement of RV



Figure 2 Echocardiographic evaluation of RV function. Yellow arrows indicate how to measure RV diameters, blue arrow indicate how to measure LV diameter in 4 chamber view to calculate RV/LV ratio. LV, left ventricle; RV, right ventricular; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging.

Box 5 Speckle tracking echocardiography for pre-operative evaluation of LVAD candidates

The evaluation of RV strain by speckle tracking echocardiography is advisable to detect subtle RV dysfunction possibly leading to post-implant RV failure.

RV strain quantification by free wall strain rather than global RV strain should be preferred since it analyses better RV intrinsic function independent from LV function.

Box 6 3D echocardiography for LVAD pre-operative evaluation

In the presence of adequate acoustic window and local expertise, 3D echocardiography may be performed for a more reliable assessment of biventricular structure and EF.

Further investigations will have to clarify whether 3DE quantification improves clinical outcomes of LVAD patients compared to conventional echocardiographic parameters.

impairment assessed by right heart catheterization,[27] and has been shown to be a marker of RV fibrosis as well.[28]

In previous studies, fwRVLS emerged as a prognostic marker in patients being considered for an LVAD, predicting early RVF,[29,30] and was included in highly sensitive prognostic scores together with haemodynamic, echocardiographic, and clinical parameters[17,31–33] with a cut-off value >−14%.

Therefore, fwRVLS may be considered the most sensitive echocardiographic parameter to identify those patients referred for an LVAD who are at greatest risk of developing post-operative RVF and therefore to aid in patient selection and determination of further management strategies. However, larger multicentre studies, such as the ongoing EuroEchoVAD trial (ClinicalTrials.gov NCT03552679), a EUROMACS-approved study including 600 patients, are needed to establish optimal reference values to aid decision-making in routine clinical practice (Box *5*).

3D echocardiography

Echocardiographic assessment of LV and RV size and function is key for candidate selection and detection of possible LVAD complications. Due to the complex shape and mechanics of the RV, 2D echocardiography (2DE) cannot reliably measure RV volumes and EF.

In the presence of adequate acoustic windows and local expertise, 3D echocardiography (3DE) is the most accurate method to quantify ventricular volumes and EF.[24] Feasibility of 80–92% is reported for RV-focused four-chamber views.[34] 3DE can circumvent all the potential limitations associated with 2DE including limited visualization, incorrect geometric assumptions, and cavity foreshortening.[35] 3DE permits a more accurate and reproducible analysis of LV and RV volumes and function than 2DE.[36] This is particularly useful in borderline cases, such as when LVEF is around 25% or RV fractional area change (FAC) is 30–35%. In LVAD implantation candidates, 3D RV volumes and EF were associated with post-operative outcome and were superior predictors of RV failure compared to conventional parameters such as 2D RV volumes and RV/LV ratio.[37–39]

Following LVAD implantation, 3DE becomes more technically challenging due to poor image quality and artefacts due to the LV apical cannula (50–56% feasibility in LVAD patients vs. 85% in non-LVAD patients).[40–42] When feasible, 3DE was helpful to reliably identify the 'cross-over point' during ramp testing (see PT), which corresponds to the LVAD speed at which there were excessive LV unloading and risk of RV dilation due to septal shift towards the LV,[43] as well as to quantify the LV reverse remodelling and shape changes that occur early after LVAD implantation.[44] New 3D technologies under development, such as 3D intracardiac echocardiography, may assist in the future with the point-of-care implantation of percutaneous LVADs in critical care settings (Box *6*).[45]

CMR

CMR advantages are unrestricted planes and high spatial resolution and tissue contrast.[46] Current European Society of Cardiology (ESC) guidelines for the management of HF assign CMR Class 1 indications for patients with sub-optimal echocardiography and suspected myocardial infiltration and Class 2 indications for detection of ischaemia and scar.[47] Although CMR thus offers clear potential for the selection of candidates for LVAD therapy, the current evidence for the use of CMR in this scenario is sparse and recommendations in this document are therefore necessarily largely based on expert opinion. Moreover, the use of CMR is limited in patients with chronic kidney failure (for contraindication to the use of gadolinium with eGFR < 30mL/min/m^2) and with non-magnetic resonance compatible devices (e.g. implantable cardioverter defibrillator).

In the selection of candidates for LVAD, CMR will generally be considered when echocardiography is either of insufficient quality or shows findings that require more detailed assessment: when information on myocardial ischaemia and viability is required or in patients with complex anatomy including those with congenital heart disease. However, obtaining high-quality CMR images requires patients to lie supine within the magnetic resonance imaging (MRI) scanner usually for 30–45 min and to be able to hold their breathing for several seconds. Many of the patients considered for LVAD therapy may therefore not able to tolerate a CMR scan during their acute presentation. Rapid CMR protocols are in development and may improve the use of CMR in these patients in the future. CMR image quality may also be affected by the presence of implantable cardiac devices, but most of these devices do not pose a contraindication to CMR.

A routine CMR scan will include anatomical images that identify the main cardiac and vascular structures and can detect mediastinal and pulmonary pathology that may be relevant in the triage for LVAD. Cine images are acquired in standardized orthogonal long-axis and short-axis planes that cover the entire heart and provide highly reliable measurements of left and RV dimensions, regional and global contractile function.[46] In particular, in patients with abnormal cardiac morphology, CMR is more accurate than 2DE in measuring ventricular size and function and can thus help guide decisions on the appropriateness of LVAD therapy in borderline cases.[48,49] Late gadolinium enhancement (LGE) CMR has become the reference standard for the detection, localization, and quantification of myocardial infarction and focal fibrosis due to its high spatial resolution and tissue contrast, which closely match and provide direct anatomical correlation of viable and non-viable myocardium.[50] The combined assessment of regional LV function, ischaemia, and scar by CMR offers accurate assessment of the potential for regional and global functional recovery to guide the need for revascularization in patients with known or suspected ischaemic heart disease considered for LVAD therapy.[51] Moreover, CMR and positron emission tomography (PET) imaging for example could be used to rule out inflammatory heart disease in patients undergoing heart transplantation diagnosed as idiopathic dilated cardiomyopathy. In some patients, LGE CMR can be complemented by low-dose dobutamine cine imaging to determine functional reserve similar to stress echocardiography.[52] Early and late gadolinium-enhanced CMR is also highly sensitive for the detection of intracardiac thrombi, providing essential information

Box 7 The use of CMR for LVAD pre-operative evaluation

CMR allows accurate measurements of left and right heart dimensions and function in patients considered for implantation of LVAD.

MR angiography can be used to assess the vascular anatomy in pre-operative assessment.

Contrast-enhanced CMR allows the detection of intracardiac thrombi with high accuracy.

Specific evidence of using CMR pre-LVAD therapy is sparse, and more prospective research is needed.

prior to cannulation of the LV.[53] Further tissue characterization can be achieved with parametric mapping, which provides information on myocardial oedema and diffuse fibrosis and, where available, may be used as a contrast-free alternative to LGE.[54] Flow velocity-encoded CMR can be used as an adjunct to echocardiography to estimate the severity of valvular disease as an important predictor of outcome following LVAD.[55] Finally, MRI angiography delineates the anatomy of the great vessels and excludes pathology such as aortic aneurysms similar to computed tomography (CT) and can help procedure planning of concomitant vascular intervention.[56]

The limited literature on the use of CMR before LVAD implantation includes a study that compared CMR with echocardiography and right heart catheterization for the prediction of significant right HF post-LVAD, a common complication with associated poor outcome (Box 7).[57]

CT

Data concerning the use of CT in the planning phase of LVAD implantation are scarce, being mostly related to the post-procedural follow-up and assessment of device-related complications.[58] Currently, CT is not routinely performed in all patients who are considered for LVAD therapy. However, recent results have shown a promising potential role in the pre-procedural evaluation of patients' eligibility and feasibility for device implantation.

The principal value of CT concerns its accurate definition of the thoracic anatomy. Imaging with CT can provide a detailed overview of the mediastinum, accurately defining the spatial relationships of the LV with the surrounding non-cardiac structures. Evaluation of the anatomical course of the great vessels, exclusion of aortic aneurysms, and congenital alterations are of fundamental importance before LVAD implantation.[24] Pre-operative assessment with CT is appropriate in patients with known congenital heart diseases to evaluate the safety and feasibility of the surgical procedure.[59] In patients with known aortic disease, pre-operative CT should be performed to exclude the need for concomitant aortic surgery.[60]

Recently, new software have been developed to achieve virtual device reconstruction and simulation of implantation through semi-automatic segmentation and 3D reconstruction of pre-operative CT scans before LVAD surgery.[61,62]

Identification of patients who may still benefit from myocardial revascularization is also fundamental prior to LVAD implantation.[62] An attempt to treat haemodynamically significant coronary stenosis should be fully addressed, as every single opportunity of myocardial recovery may strongly influence LVAD planning. According to latest guidelines, coronary CT angiography (CCTA) is appropriate to exclude the presence of coronary artery disease (CAD) in HF patients with low to intermediate pre-test probability of CAD or in cases when results from other non-invasive stress tests are uncertain.[3] In these patients, beyond pure anatomical definition of coronary stenosis, advanced techniques, such as fractional flow reserve-CT and myocardial perfusion imaging with CT perfusion, could be considered to unmask haemodynamically significant coronary lesions and presence of myocardial ischaemia, as an alternative to other functional imaging stress tests.[47]

Another important issue before LV cannulation concerns the detection of intracardiac thrombi, which is fundamental to avoid thromboembolic events in the peri- and post-operative phase. On cardiac CT, thrombi typically appear as hypodense lesions that persist on delayed acquisition sequences (60–90 s after contrast injection).[47] Cardiac CT is considered an appropriate alternative to TOE to rule out left atrium and left atrial appendage thrombosis thanks to its high sensitivity and specificity.[63] Moreover, CT can provide a multiplanar view of all cardiac structures and is not limited by acoustic windows or acoustic shadowing like echocardiography. However, the possible CT artefacts that may mimic left atrial appendage thrombus should be considered and excluded.

As already mentioned, before LVAD implantation, the presence of significant aortic or TR, RV dysfunction, and intracardiac shunts should be evaluated to avoid post-implant complications.[62] However, according to a recent consensus document, cardiac CT could be helpful to assess ventricular volumes and function in selected cases where echocardiographic data are uncertain and/or CMR is limited or contraindicated,[47] as many of these patients are already implanted with cardiac defibrillators.[64]

In contrast to larger echocardiographic data, specific CT parameters, which prognostically can represent predictors of post-operative complications, increased morbidity and mortality after LVAD implantation, have not yet been defined. Moreover, no data are available on the use of CT delayed enhancement for scar assessment[65] in planning LVAD surgery. Further larger studies are warranted to explore the role of CT in these scenarios.

Moreover, technological advances and strategies for radiation dose reduction could further help expand the role of CT in the selection of patients for LVAD therapy as a complementary test to other imaging modalities (*Table 3*). However, like CMR, this resource remains limited in patients with severe reduction of renal function (Box *8*).

Peri-implantation assessment

The assessment of LVAD recipients in the peri-LVAD implantation period predominantly involves (i) TOE that should always be performed

Table 3 Role of different imaging modalities in the pre-operative assessment for LVAD.

	Echo	CT	CMR
LV function	++	+	+++
LV filling pressures	+++	+	+++
RV function	++	+	+++
Thoracic anatomy	++	+++	++
Vascular anatomy	+	+++	++
Valves	+++	+	++
Shunt	++	+	+++
Ischaemia	+	+	+++
Scar	+	+	+++
Thrombus	++	+++	+++
Fibrosis	+	++	+++
Oedema	+	+	+++

+, useful but not conclusive; ++, very useful; +++, mandatory.

Box 8 The use of cardiac CT for LVAD pre-operative evaluation

Cardiac CT allows accurate definition of thoracic anatomy and assessment of congenital alterations or aortic aneurysms before LVAD surgery.

Cardiac CT with delayed imaging can exclude the presence of intracardiac thrombi with high sensitivity and specificity.

CT angiography can be used to assess the vascular anatomy in pre-operative assessment.

Further studies are needed to evaluate the role of CT to prevent post-procedural complications.

during the LVAD implantation surgery and (ii) TTE that, in conjunction with TOE, is used early post-operatively in the intensive care unit. Other imaging modalities are seldomly utilized in this peri-operative period.

Pre-implantation TOE

A comprehensive TOE evaluation of LVAD candidates in the operating theatre should precede LVAD implantation and is typically an extension of prior comprehensive MMI performed during assessment of LVAD candidacy and pre-operative planning. The immediate pre-implantation TOE should include, but should not be limited to, the evaluation of potential intracardiac thrombi and shunts, as well as RV size and function and AV structure and function.[6,66] A thorough assessment of a potential PFO should thus be undertaken, including colour Doppler evaluation of the fossa ovalis at low settings of the Nyquist limit and intravenous injection of agitated saline, which in some cases may be required in conjunction with a ventilator-driven Valsalva manoeuvre to unmask shunting.[6,65] Despite such attempts, in some cases, only a decrease in left atrial pressure following LVAD initiation will unmask the existence of a PFO.[6] In regard to thrombi, all cardiac chambers should be examined, particularly the left atrial appendage (of note, some centres perform concomitant surgical left atrial appendage occlusion) and the LV apex (particularly around the site of the apical cannulation, where an apical thrombus needs to be brought to the surgeon's attention). Other relevant points to assess should be based on prior imaging examinations as well as the clinical status of the patient; e.g.: (i) in case of any suspicion of endocarditis, possible vegetations should be excluded (if confirmed, endocarditis is a contraindication for LVAD implantation); (ii) in some cases, an extended evaluation of the AV may be required (however, the degree of aortic regurgitation is best assessed prior to surgery, as it may be underestimated in the context of general anaesthesia)[6,66]; and (iii) the assessment of the morphology of the ascending aorta for dissection, aneurysm, plaques, and calcifications may also be needed in planning the location of the outflow graft anastomosis.

TOE during implantation

The peri-operative TOE examination during LVAD implantation includes the guidance of the site of apical coring for the insertion of the inflow cannula of the LVAD. This is performed by imaging the heart in the mid-oesophageal four-chamber view during external compression of the apical area (by surgical instrument or finger), directed towards the mitral valve orifice, with the aim of positioning the inflow cannula in this direction.[67] Further procedures include continuous monitoring for possible air bubbles in left-sided chambers (including the LV apex and inflow cannula area), aorta, and the outflow graft anastomosis during the implantation and de-airing procedures.[6] Complete closure and lack of residual communication between the left atrium and appendage should be confirmed by TOE in those undergoing left atrial appendage occlusion.[68] The monitoring of RV function is described in the following subsection.

TOE during LVAD activation and pump speed optimization

TOE is an irreplaceable tool in haemodynamic monitoring during LVAD implantation, complementing invasive haemodynamic monitoring. During LVAD activation and pump speed optimization, LVAD settings (speed and flow) should be documented on the echocardiographic images. One of the primary determinants of the speed of cardiopulmonary bypass weaning (in those implanted on-pump) and increment in LVAD speed is the balance between left and right heart loading conditions, as evidenced by the position of the interatrial and IVS, as well as the size and function of left- and right-sided chambers. This predominantly entails the assessment of RV size and function, along with the assessment of TR, which could determine the capability of the RV to accommodate the increase in preload after LVAD activation. Additionally, LVAD speed settings that are excessive in the setting of a failing RV may induce a 'sucked-down' underfilled/over-decompressed LV.[6] Depending on the intraoperative TOE and haemodynamics, in conjunction with the assessment of RV function prior to the LVAD implantation, the occurrence of RV dysfunction during LVAD activation may require pulmonary vasodilators to reduce RV afterload, lower LVAD speed settings to reduce RV preload, short-term inotropic support, or peri-operative temporary RVAD implantation in patients unresponsive to these attempts. In cases of brief and transient RV dysfunction, a careful and slower speed optimization of the LVAD may allow for restoration of RV function and the possibility of restoring medial positions of the interatrial septum and IVS.

Another indication of an appropriate LVAD speed setting is the opening of the AV, which should be assessed in conjunction with the RV and LV size and function (*Figure 3*).

In patients with HeartMate II or 3 or HeartWare HVAD, a constantly closed AV may indicate maximal LV unloading; intermittent AV opening usually indicates good LV unloading; while a constantly opened AV may indicate inadequate offloading that suggests additional escalation of LVAD speed in order to increase LV unloading—the ultimate choice among these strategies is centre specific.

Nevertheless, patients with LVADs characterized by a different pump system that lowers device work for 9 s each minute [intermittent low speed (ILS) phase, typical of Jarvik 2000 device], have a different AV opening pattern. In case of correct function, AV should open only during the ILS phase.

A dilated RV with TR, septal shifts towards the left-sided chambers, and a small LV with a closed AV suggest the need for a reduction in LVAD speed; a dilated LV with a septal shift towards an unenlarged RV and a fully opening AV suggest the need for an increase in LVAD speed. In some case, looking at the atrial septal shift may be useful for this purpose as well. The presence and severity of aortic regurgitation should be assessed in addition, as previously described—in the event of unmasked significant aortic regurgitation after LVAD activation, an additional surgical procedure may be considered.[67]

It is also important to assess the position of the inflow cannula and the outflow graft. The inflow cannula should be positioned within or near the LV apex, parallel to the IVS, with its opening directed towards the mitral valve—an excessive angulation towards the IVS or the LV free wall might require surgical revision. Doppler interrogation of the inflow cannula and outflow graft should be performed. This could be done by pulsed Doppler interrogation adjacent to the structure of interest, using a four-chamber apical view for inflow cannula and left or right (in right lateral decubitus) parasternal views or suprasternal view for outflow graft (Box 9).



Figure 3 AV opening pattern in different types of LVAD, which is useful to recognize optimal and pathologic conditions, and relative possible causes of abnormalities.

Box 9 Peri-implantation assessment of LVAD recipients

Peri-procedural imaging predominantly involves TOE (during LVAD implantation surgery) and TTE (both may be used early post-operatively), while other modalities are typically not utilized in this period.

The pre-implantation TOE involves (but is not limited to) the evaluation of potential intracardiac thrombi and shunts, RV size and function, and AV structure and function.

Peri-operative TOE during LVAD implantation includes:

- guidance of the site of apical coring for the insertion of the inflow cannula
- monitoring for intracavitary/intra-aortic air bubbles

Peri-operative TOE during LVAD activation and pump speed optimization focuses on the balance between left and right heart loading conditions by assessing:

- position of the interatrial septum and IVS
- size and function of left- and right-sided chambers
- AV opening
- assessment of tricuspid regurgitation

Early post-implant complications

Cardiac tamponade

Cardiac tamponade associated with cardiac surgery may occur within the first 24 h or late (arbitrarily defined as >5–7 days) after cardiac surgery. Early tamponade is usually related to bleeding, while late tamponade is often multifactorial.[69] Patients undergoing LVAD implantation have higher risk of early tamponade because of (i) pre-implantation coagulopathy related to anti-thrombotic therapy or temporary MCS; (ii) early post-operative anticoagulation and antiplatelet therapies; and (iii) acquired (LVAD-related) coagulopathy.

Haemodynamic parameters such as raised right atrial pressure and low cardiac output unresponsive to fluid challenge cannot distinguish tamponade from RVF following LVAD implantation. TTE is sometimes difficult in the early post-operative setting, and TOE may be helpful (Box *10*). However, the diagnostic value (e.g. sensitivity and specificity) of echocardiographic parameters for cardiac tamponade has not been systematically evaluated in patients with LVADs.

Traditional echocardiographic criteria such as exaggerated respiratory variation in mitral inflow pattern have limited utility during positive pressure ventilation.[70] In addition, inferior vena cava diameter and hepatic venous flow may not differentiate tamponade from RVF, especially with concomitant TR. Continuous LV drainage by the LVAD may further complicate the diagnosis. For example, pulsus paradoxus and changes in aortic flow velocity cannot be appreciated in the absence of pulsatility and LV ejection. Leftward shift in the IVS and LV collapse may be features of excessive pump speed and RVF.



Figure 4 Evaluation of IVS position in patients with LVADs is fundamental to recognize different haemodynamic abnormalities possibly causing leftwards or rightwards IVS shift.

In the face of these challenges, diagnosis must rely on high index of clinical suspicion and serial clinical, haemodynamic, and echocardiographic assessments. Increasing pericardial effusion with right heart chamber collapse can distinguish tamponade from right HF. M-mode imaging may identify the timing and duration of right atrial and RV collapse. In general, the longer the duration of compression, the more severe the tamponade.[71] Finally, clinicians should be cognisant that RVF and tamponade may coexist; the diagnosis of one does not preclude the other.

RV failure

RV dysfunction is one of the main adverse consequences after LVAD implantation. Right HF is a major cause of mortality early post-LVAD implant. RV dysfunction may be transient following cardiopulmonary bypass or transient RV ischaemia from air emboli. However, persistent RV dysfunction may develop for various reasons. Excessive increase in RV preload, peri-operative elevations in the pulmonary vascular resistance, a shift in the IVS position altering RV geometry and function or the function of the tricuspid valve annulus, ischaemic injury of the RV, and atrial dysrhythmias can all lead to worsening RV function following LVAD implantation.[72] Alternatively, RV function can improve after LVAD implantation, in particular in patients with end-stage HF who have a degree of RV dysfunction due to post-capillary pulmonary hypertension.

RV dysfunction can develop due to excessively high LVAD pump speeds that can lead to (i) excessive RV preload and (ii) impairment of LVAD flows and consequently an LV suction event when the LVAD inflow cannula 'sucks down' on the LV wall, potentially causing haemolysis or ventricular arrhythmias.

Imaging parameters should always be assessed in conjunction with clinical and haemodynamic features of RV failure. Echocardiography is the primary imaging modality in evaluating RV function in LVAD patients. Assessment of the RV includes an assessment of RV shape, size, volume, wall thickness, radial and longitudinal contractility, IVS shift towards LV or RV, evaluation of the right atrial size, main pulmonary artery and its branches, inferior vena cava size and its respiratory alterations, tricuspid valve annulus, and degree of TR.[73] Increased RV size and worsening TR indicate worsening RV function after LVAD. Tricuspid annular plane systolic excursion (TAPSE) becomes less sensitive in assessing RV function after cardiothoracic surgery. The improvement in RV afterload and contractility could lead to reduction of TAPSE due to increase in RV stroke volume. However, reduced TAPSE along with RV dilatation and worsening TR indicates worsening RV function.[74]

Echocardiographic parameters correlated with RV failure after LVAD implantation include quantitative RV dysfunction, TAPSE, FAC, RV short-axis to long-axis ratio, RV end-diastolic dimension to LV end-diastolic dimension ratio, tricuspid annular dilatation without significant TR, TR duration corrected for heart rate, peak systolic (S′) velocity of the RV free wall at the tricuspid annulus assessed with tissue Doppler, early diastolic (E′) velocity of the RV free wall at the tricuspid annulus assessed with tissue Doppler, RV index of myocardial performance, RV systolic and diastolic longitudinal strain, RV E/E′ ratio, TAPSE increase in response to dobutamine infusion, severity of TR, and 3D RV end-systolic and end-diastolic volume index (Box *10*).[75]

Inadequate or excessive LV unloading

LVADs are excellent at unloading the LV, as reflected by subsequent reductions of LV size, and improvements in IVS position and LV systolic function. The ability of LVADs to provide haemodynamic offloading is dependent on preload, afterload, and pump speed.

IVS shift to the right could be due to inadequate LV unloading due to low pump speed, whereas IVS shift to the left could indicate excessive LV offloading due to high pump speed (*Figure 4*). Improvement in the degree of mitral regurgitation—or lack thereof—is a marker of the



Figure 5 M-mode echocardiography and colour Doppler application for the evaluation of aortic regurgitation in patient with LVADs: this figure shows pan-cardiac cycle aortic regurgitation in a patient with HeartMate 3.

adequacy of LV offloading, as it reflects changes in LV end-diastolic pressures.

Assessment of AV opening is crucial for the evaluation of LV unloading (Box *10*). AV opening is affected by LVAD pump speed, native LV function, and LV preload and afterload. Low pump speed often leads to normal or intermittent opening of the AV in relation to the cardiac cycle accompanied by larger LV dimensions. AV opening is best assessed by M-mode echocardiography at the AV level. It is worthy to mention that the choice of optimum LVAD pump speed varies between centres as some prioritize intermittent AV opening while others aim at optimizing best LV unloading while leaving AV closed.[6] It is advised that LVAD speed be set as low as possible to allow at least intermittent valve opening; however, this may not be possible in the context of severely impaired native LV function; therefore, pump speed should not be set so low to allow AV opening at the expense of adequate LV unloading and HF symptoms.

Excessive offloading of the LV with high LVAD pump speeds can lead to a suction event in which the LVAD inflow cannula sucks down on the LV cavity leading to an abrupt drop in LVAD flows. This can develop due to the excessive decompression by the LVAD and/or subsequent RV dysfunction that impairs LVAD filling. Accurate assessment of the frequency of AV opening requires recording of multiple cardiac cycles (five to six) at a slow sweep speed (25–50 mm/s). Assessing AV opening requires using both M-mode and 2D assessment as M-mode assessment alone could give a false impression of AV opening (pseudo-opening) due to off-axis imaging that should be suspected if AV opening appears fusiform.[6] Colour M-mode can also be used in the presence of aortic regurgitation (*Figure 5*).

If the AV is closed, it important to evaluate for the presence of AV and root thrombosis that can develop with or without commissural fusion as well as evaluation for new-onset aortic regurgitation.

Infections

Device infection is a common complication after LVAD implantation. This may involve the device driveline, the pump itself, the inflow cannula or outflow graft, and the pump pocket.[76] The LVAD driveline is frequently involved as the initial source of infection (10–35% of all cases), especially at the entry site in the skin.[77] Additionally, fibrin deposition on the device and cannula surfaces favours bacterial colonization.[78] Vegetations can be observed, as well as destructive valve lesions and abscesses in the surrounding cardiac structures, typically developed adjacent to the device. Presence of fever, leucocytosis, elevated inflammatory markers, and a purulent drainage around the driveline should strongly raise the suspicion for LVAD infection.[79]

Echocardiography should be firstly performed to confirm clinically suspected device infection (Box *10*). TTE allows the detection and sizing of vegetations, can assess involvement of the surrounding cardiac structures, and should also be repeated after device extraction to rule out residual vegetations.[80] TOE demonstrated a higher sensitivity and specificity for LVAD infection than TTE and should be performed when transthoracic findings are uncertain and/or the clinical suspicion is high. False negative findings for TTE are mainly due to inadequate acoustic windows, presence of reverberation artefacts due to metallic components, and limited planar views.[81]

Second-level imaging with cardiac CT can help confirm the diagnosis and assess the extent of the infected sites. Typically, on CT imaging, infections present as gas or fluid collections around the cannulae or on the device surface, while masses within the cannulae may be imaged as well. Additional, highly suggestive features are the presence of rim enhancement and soft tissue components as signs of inflammation.[82] Detection of LVAD infection with CT may, however, also be limited by artefact due to the device and driveline.

When diagnostic uncertainty persists regarding possible LVAD-related infections and risks of surgical exploration are high, then fluorodeoxyglucose (FDG)-PET/CT may be useful. In fact, although TTE, TOE, and CT are characterized by good sensitivity for the detection of LVAD infections, these provide non-specific information regarding increased wall thickness, fluid accumulation, abscess formation, and fistula.

FDG PET/CT has shown high diagnostic accuracy in localizing device infection and its internal extension, with an overall sensitivity and specificity of 92 and 83%, respectively.[83] Indeed, PET/CT can distinguish between the wide range of LVAD-related infections, such as those related to pump and cannula, pump pocket, and superficial and deep driveline infections. Combined use of PET and CT helps in identifying areas with increased metabolic activity with high spatial resolutions. Therefore, knowing the precise localization and extension of an infection source may guide subsequent treatment, whether prolonged antimicrobial therapy, LVAD exchange, or heart transplant. It has also shown higher diagnostic accuracy compared to radiolabelled leucocyte scintigraphy single-photon emission CT.[84]

Beyond its high diagnostic power, the PET/CT pattern of radiotracer uptake has demonstrated important prognostic value and is relatively unaffected by device-related artefact.[85] Inaccurate results may occur during the peri-operative period because of the possible uptake of pledgeted surgical suture material in typical locations. Also, attenuation correction used to enhance image quality can produce artefacts surrounding LVAD metallic components; therefore, possible uptake should be confirmed in non-attenuated images as well. On the contrary, antibiotic use may lead to underestimation of the FDG uptake in areas of infection. Finally, careful metabolic preparation to drive myocyte metabolism towards fatty acids instead of glucose should be performed prior the examination.[83]

Aortic regurgitation

A competent AV is a pre-requisite for optimal LVAD function. First of all, AV opening prevents aortic root thrombosis and reduces tissue remodelling and cusp fusion, which represent the main cause of LVAD-related aortic regurgitation. Aortic regurgitation creates a 'short circuit' in the LVAD–aortic blood flow pathway and results in a drop in antegrade flow and ineffective unloading of the LV. Current consensus recommends concomitant bioprosthetic AV replacement surgery for moderate or severe aortic regurgitation during LVAD implantation.[86] Assessment of the AV is mandatory pre- and intra-operatively. Thus, severe aortic regurgitation in the early post-operative period is unusual and largely preventable.

In some cases, aortic regurgitation may develop following AV replacement due to paravalvular leak. The assessment of the severity of paravalvular leaks is especially challenging in patients with LVAD due to the nature of continuous blood flow. Several echocardiographic features of significant aortic paravalvular leak have been described,[87] such as short pressure half-time, 'dense' regurgitation jet on continuous-wave Doppler imaging, vena contracta >0.6 cm, descending aorta diastolic flow reversal, regurgitant fraction >50%, and increased systolic transvalvular gradient despite normally functioning prosthesis. However, many of these parameters are not applicable in the setting of LVAD and may also underestimate the severity as regurgitation may span the cardiac cycle. Dynamic assessment with ramp testing showing the lack of reduction in LV volume with increase in LVAD flow also provides supportive evidence of severe aortic regurgitation. In ramp test, echocardiography is repeatedly performed at incremental pump speed. A typical protocol starts with a pump speed of 8000 rpm, which is then increased by 400 rpm every 2 min (Box *10*).

Thrombosis

According to MOMENTUM 3 trial 5-year results, thrombosis is reported in 10% patient/year with axial-flow pump devices and 1% patient/year with centrifugal-flow pump devices after LVAD implantation.[88] The pump system, the inflow cannula, and the outflow cannula may all be involved, as well as the cardiac cavities and the aortic root. CF systems favour patterns of shear stress, which activate the thrombogenic cascade, while dislocation or kinking of cannulas may also facilitate thrombosis.[89] Clinical suspicion arises with decline of pump performance, increase of pump consumption, and signs of overt haemolysis or ischaemic stroke.

The first-line imaging modality to assess device thrombosis is echocardiography (Box *10*). Inflow cannula thrombosis can result in cannula obstruction, which is characterized by elevated flow velocities and turbulent flow on colour Doppler.[90,91] Relevant PT should be suspected in the presence of LV dilatation and severe (or worsening) mitral regurgitation, insufficient LV unloading with continuous opening of the AV, and regurgitation through both cannulae with increased systolic-to-diastolic velocity ratio.[6]

Laminated thrombi may develop even on the aortic root due to a persistently closed AV, generally involving the non-coronary cusp but sometimes causing massive thrombosis of the whole aortic root with high embolic risk. At this level, TOE may be particularly advantageous, and valvular thrombosis typically appears with thickening and restricted motion of valve leaflets.[92] Maintenance of intermittent valve opening through modification of LVAD speed may be useful in non-pulsatile LVADs to avoid this complication,[93] but the valve may not open adequately even with reduction of pump speed in some case. The use of ultrasound-enhancing agents (UEAs) can also help with the interpretation of other important TTE features such as inflow cannula inlet malposition and intracardiac and/or aortic root thrombus.[7]

CT can accurately confirm and assess the extension of thrombosis (*Figure 6*). Most devices are not MRI compatible, while CT can allow

Box 10 Short-term complication assessment of LVAD recipients

Serial echocardiographic evaluation, together with clinical and haemodynamic monitoring, is fundamental to recognize cardiac tamponade. Increasing pericardial effusion with right atrial/RV collapse is the most helpful feature for diagnosis and severity assessment.

Echocardiography is the first imaging modality in evaluating early RVF after LVAD implantation and is advisable to perform it in all patients. Advanced echocardiography (speckle tracking, 3D) may offer additional information about RV early dysfunction and size.

IVS shift, mitral regurgitation, and aortic valve opening must be assessed to recognize inadequate or excessive LV unloading.

Echocardiography, particularly TOE, has shown high sensitivity and specificity to detect LVAD infections. However, CT and PET/CT may be used in doubtful cases for higher diagnostic accuracy or to assess the extension of device infection.

A ramp test demonstrating a lack of reduction in LV volume with an increase in LVAD flow is highly suggestive of severe aortic regurgitation in LVAD patients.

Echocardiography is the first-line modality to assess thrombosis and cannula obstruction. TOE may be useful in case of valvular thrombosis. UEAs may help recognize thrombosis and inflow cannula malposition. CT may be appropriate to confirm and assess the extension of thrombosis or in cases of ongoing clinical uncertainty.

TTE and TOE using colour and spectral Doppler modes, possibly completed with a ramp test, is advisable to assess blood flow via the inflow cannula and the outflow graft.

Chest CT angiography with 3D reconstruction may be appropriate in all LVAD recipients post-operatively to assess inflow and outflow cannula malpositioning.



Figure 6 Representative case: a 75-year-old male with end-stage ischaemic cardiomyopathy who underwent placement of a LVAD (Jarvik 2000). He was admitted to the hospital because of repeated Jarvik alarms. CTA of the chest showed an eccentric thrombus causing a severe stenosis at the distal portion of the outflow cannula, subsequently treated by the placement of Optimed Sinus-XL 6F 16 × 120 mm stent.

Table 4 LVAD-related complications assessment by echocardiography/CT/CMR

	Echo	CT	CMR
Thrombosis	Signs of cannula and pump dysfunction, laminated thrombi on the aortic root, intracardiac thrombi	Hypoattenuation areas on contrast-enhanced CT at delayed imaging (60–90 s)	Most devices are not CMR compatible
Infections	Vegetations on device and cannula surfaces, abscess, destructive valve lesions	Rim-enhancing fluid collections with gas locules and soft tissue components on contrast CT	Most devices are not CMR compatible
Aortic regurgitation	Use of colour Doppler Measurements of qualitative–quantitative parameters Left ventricular enlargement	Classification of regurgitation type Quantification of aortic regurgitant orifice Exclusion of aortic dissection	
Inflow/outflow graft abnormalities	Inflow cannula: turbulent flow with elevated velocities via continuous-wave Doppler should raise a suspicion of cannula obstruction. The normal filling velocity is between 1 and 2 m/s, depending on the preload and the intrinsic LV function. The outflow graft: anastomosis to the ascending aorta can be visualized approximately at the level of the right pulmonary artery. Evidence of high velocities (>2.0 m/s) can be indicative of obstruction of the outflow graft		
Cardiac tamponade	Right heart chambers collapse IVC dilatation and abnormal hepatic venous flow		
Right ventricular failure	2D echocardiographic assessment of RV size, function, and interventricular septum position fwRVLS is most accurate in assessing RV function before and after LVAD implantation		

fwRVLS, free wall right ventricular longitudinal strain IVC, inferior vena cava; LV, left ventricle; LVAD, left ventricular assist device; RV, right ventricle.



Figure 7 Possible complications of outflow graft detected by cardiac CT.

complete visualization of the inflow and outflow cannulae with the sites of anastomosis[94] (*Table 4*). The thrombi typically appear as low attenuation areas with focal filling defects on contrast-enhanced CT scans.[95] CT has demonstrated a high sensitivity and specificity of 85 and 100%, respectively, in detecting cannula thrombi when using surgical findings as reference standard.[96] Moreover, when a pump exchange is being considered, CT may not only help confirm that structures are mechanically compromised but can also facilitate planning of surgical device exchange.[97]

Inflow cannula/outflow graft abnormalities

Several complications have been described in relationship to or involving the LVAD inflow cannula, which can lead to adverse outcomes. Proper positioning of the inflow cannula within the apex and in relation to the IVS is crucial to avoid septal shift and consequently RVF. Importantly, inflow cannula depth and angulation in relation to the long axis of the LV can change during the course of LVAD support and play a role in reducing intraventricular thrombosis and/or PT.[98–100]

Likewise, the LVAD outflow graft is a site for several, potentially serious complications including narrowing, kinking, obstruction, infection, and thrombosis. The accumulation of biodebris has been reported within and around the outflow graft in patients with CF-LVAD such as HeartMate 3. Jain and colleagues recently reported outflow graft narrowing in one-third of HeartMate 3 recipients. Furthermore, the longer the duration of support, the higher the chance for an outflow graft narrowing. Significant outflow graft narrowing (due to biodebris) could be defined as any hypodense material accumulation of at least 3 mm at any point along the outflow graft, either within or distal to the bend relief.[93,101,102] The HeartMate 3 pump includes a bend relief structure premade with a radiopaque Gore-Tex (W. L. Gore & Associates) tube surrounding the proximal portion of the outflow graft to prevent graft kinking.[103] This radiopaque material facilitates fluoroscopic and CT assessment of kinking.

Overall, TTE and TOE using colour and spectral Doppler modes allow the assessment of blood flow via the inflow cannula and the outflow graft. Chest CT angiography with 3D reconstruction may be of additional use in all LVAD recipients post-operatively to assess inflow cannula position, thrombus formation, or obstruction[104] (*Figure 7*). Likewise, chest CT angiography allows the assessment of outflow graft patency, twist, kinking, and position. In addition, ramp test and machine log file analysis are advised in all cases with suspected inflow or outflow graft complications.

Post-implantation: follow-up

Follow-up of LVAD carriers is expected to be performed by LVAD centres and non-specialized centres in a shared manner, as patients may not have easy access to LVAD centres. Clinical follow-up may be carried out by non-specialized centres while comprehensive evaluations should be routinely performed in LVAD centres. Timing of follow-up varies depending on time from intervention, being more frequent in the first year. Echocardiography plays a major role in follow-up visits, by providing important information regarding haemodynamic status, heart valve functioning, reverse remodelling, and guiding treatment optimization (Box *11*) (*Table 5*).

LV unloading

LV unloading with an LVAD results in reduction of LV dimensions and volume compared to pre-implantation measurements. The most used parameter for serial assessment at follow-up is the electrocardiogram (ECG)-gated diastolic LV internal diameter measured in the parasternal long-axis view. This is because the inflow cannula can obscure the LV apex endocardial border in apical views, reducing the accuracy of LV volume calculation in bi-plane views and resulting in underestimation of the LV volume. The ECG-gated systolic LV internal diameter is also measured in parasternal long-axis view and compared to the

Table 5 Follow-up TTE checklist

Heart structure	Parameters
Left ventricle	LV dimensions (LVEDD, LVEDS)
	LV systolic function (LVEF, LVGLS)
	LV diastolic function (E/A, e′ septal, e′ lateral, E/E′, LAVI, LA strain)
Left atrium	LA dimensions (LA area and volume index)
	LA function (LA strain)
Heart valves	Mitral annulus dimensions, leaflet and papillary muscle geometry, and mitral regurgitation degree
	Aortic valve morphology, cusps' fusion, valve opening, and regurgitation degree
	Tricuspid annulus dimensions and regurgitation degree
	Prosthesis position and function, paravalvular regurgitation
Right ventricle	RV dimensions (RV basal, longitudinal, and medium diameter)
	RV function (TAPSE, TDI s′, RVFAC, RVSI, RV free wall strain)
Pulmonary pressure	sPAP
Other	Interventricular septum position
	Distance from inflow cannula and interventricular septum
	Aortic root thrombosis
	Pulsed Doppler interrogation of inflow cannula and outflow graft

EDD, end-diastolic diameter, ESD, end-systolic diameter; E′, mitral annular velocity by tissue Doppler imaging; E/A, early diastolic wave/late diastolic wave ratio by pulsed-wave Doppler; LA, left atrium; LAVI, left atrial volume index; LV, left ventricle; sPAP, systolic pulmonary artery pressure; RV, right ventricle; RVFAC, right ventricular fractional area change; RVSI, right ventricular sphericity index; TAPSE, tricuspid annular plane systolic excursion; TDI s′, systolic wave velocity by tissue Doppler imaging.

Box 11 Short-term follow-up of LVAD recipients for complications

The evaluation of TE LV internal diameter, mitral regurgitation, and estimated left atrial pressure based on pulsed-wave and tissue Doppler measures is advisable to assess LV unloading.

The assessment of aortic valve opening and thrombosis is advisable, even though differences among different devices should be taken into account.

Serial echocardiographic exams and right heart catheterization are advisable after LVAD implantation to evaluate possible myocardial recovery and criteria for LVAD explantation.

diastolic diameter. A smaller diastolic than systolic diameter suggests excessive LVAD unloading. However, it can be also the result of severe volume overload of an impaired RV, with consequent displacement of the IVS towards the unloaded LV.

LV unloading results as well in a reduction in mitral regurgitation severity and drop in trans-mitral E-wave velocity and estimated left atrial pressure based on E/e′ ratio.

Impaired unloading due to LVAD dysfunction will be suggested by an increase in dimensions and volumes of the LV and increase in mitral regurgitation severity and/or in E/e′.[6]

AV opening

Continuous flow through the LVAD into the aorta simultaneously pressurizes the aortic root and reduces LV preload (lowers LV pressure and stroke volume), a combination that reduces the frequency and magnitude of AV opening. This can be observed on 2D transthoracic or transoesophageal imaging and can be recorded on M-mode through the long axis of the AV, to allow high frame rate imaging and consequent accurate and reproducible measurement of leaflet separation and of the duration of opening. Importantly, differences among LVAD devices should be taken into account (*Figure 4*): Jarvik 2000 has an ILS mode during which AV opening occurs, while in patients with HeartMate 3, the AV should open each three to four beats, in normal conditions. Colour M-mode provides the added value of assessing the existence and duration of actual forward flow through the AV, particularly when only minimal separation of cusps is observed. Increased opening, more regular opening, or opening at every cardiac cycle of the AV suggests decrease in LV unloading, recovery of LV contractility, and/or reduction in systemic peripheral resistances. Ideally, the LVAD pump speed should be programmed at a level that is high enough to provide adequate unloading and flow, yet low enough to allow some intermittent AV opening. However, when the LV contractility is extremely poor, AV opening may not happen at all at the LVAD speed needed to achieve unloading.

If the AV remains closed in all cardiac cycles, aortic root thrombosis and fusion of the AV cusps can be observed, and it must be excluded at every assessment during follow-up. LVAD speed reduction to facilitate intermittent AV opening should not be attempted in case of suspected thrombosis of the aortic root, to avoid embolization.

LV unloading creates haemodynamic settings favourable for the development of new aortic regurgitation or worsening of pre-existent aortic regurgitation, because of higher pressure in the aortic root and ascending aorta than in the LV outflow tract (LVOT). This aortic regurgitation can be continuous and not only diastolic resulting in a higher regurgitant volume for a certain regurgitant area and difficulties in accurate quantification or estimation. New aortic regurgitation is more common in cases of complete lack of AV opening in systole and aortic root thrombosis.[6]

Myocardial recovery

Significant myocardial recovery with subsequent successful LVAD explantation has excellent outcomes but was possible only in 1.4% in the recent analysis of EUROMACS Registry.[105] In a preliminary

multicentre prospective study, aggressive pharmacological and regular monitoring of cardiac function to maximally unload the LV resulted in a high rate (40%) of successful LVAD explantation.[106] For these goals, regular low-speed echocardiograms and invasive right heart haemodynamic measurements were obtained to test the myocardial reserve.

LVAD explantation was deemed achievable if the following echocardiographic and haemodynamic criteria were met:

- Regression of the LV dilatation [LV end-diastolic diameter (LVEDD) <60 mm, LV end-systolic diameter (LVESD) <50 mm] and significant improvement in LV function (LVEF >45%).
- LV end-diastolic pressure or pulmonary capillary wedge pressure ≤15 mmHg.
- Resting cardiac index >2.4 L/min/m^2.
- Maximal exercise oxygen consumption >16 mL/kg/min (optional criterion).

However, protocols for LVAD weaning are heterogenous with no consensus or standardization.[107–109] A recent review summarized the evidence in the literature and formulated an approach to the assessment of potential myocardial recovery and LVAD explantation.[110] Progressive pump speed up-titration during outpatient follow-up is probably needed for optimal LV unloading to promote recovery and prevent the LVAD-related RVF.[111] However, RV function does not always improve concomitantly with LV offloading, and the prevalence of AV regurgitation progressively increases during LVAD pump speed up-titration.

Given the increasing number of patients with LVAD as a destination therapy, and yet with relatively limited survival compared to heart transplantation (median survival of ~5 vs. 15 years, respectively), further studies are urgently needed to define the optimal pharmacological treatment, mechanical unloading, and weaning protocols for patients with LVADs.[112]

Long-term complications

Right ventricular failure

It has long been recognized that a subset of patients fails to thrive after LVAD implantation, and this failure to thrive may be related to late right HF.[72] A number of studies have described late right HF[73] but uniform diagnostic criteria are lacking. In a recent registry study, right HF was simply defined as documented evidence of manifestations of elevated central venous pressure (e.g. peripheral oedema, ascites, or abnormal liver biochemistry) and documentation of elevated central venous pressure (e.g. directly measured right atrial pressure or distended inferior vena cava). Based on this registry, right HF requiring inotropes or RV assist device at 3 months following LVAD implantation was associated with poorer survival at a year.[74] In practice, right HF is usually diagnosed on the basis of clinical features of congestion, low LVAD flow, and suction events, in conjunction with echocardiographic features such as RV and inferior vena cava dilatation and TR.

Long-term right HF after LVAD implantation may be related to intrinsic RV cardiomyopathy or excessive LVAD output, however, also inadequate LV unloading should be excluded. Causes of inadequate LVAD unloading include inappropriate LVAD settings, aortic regurgitation, or outflow graft obstruction. Echocardiographic assessment during follow-up, including ramp studies, should be performed to optimize LVAD function and LV unloading (Box *12*). Finally, the use of combined echocardiographic and haemodynamic ramp studies has been shown to optimize the assessment of LV and RV loading status and LVAD speed settings.[75] CT imaging of the outflow graft may be appropriate in the setting of reduced LVAD flow.

In case of poor acoustic window, recent investigations showed that the use of UEAs provides substantial improvement in the examination of RV dimension and global and regional contraction with the use of UEAs, replacing some measurements from normal to abnormal leading to an improved echocardiographic assessment of the patients.[25]

Pump thrombosis

Late PT is reported in 2–6% of cases (HeartMate II device), and it is associated with increased risk of stroke and mortality, in addition to prolonged hospital readmissions.[113]

PT may occur in the circuit and/or in the pump resulting in increased afterload, low flow, and high-power alarms on the controller.[111] If unidentified and untreated with intensified anticoagulation, PT may result in worsening clinical or haemodynamic instability, requiring surgical device exchange or urgent heart transplantation.[114]

PT is often associated with changes in device parameters such as increased pump power (≥2 W above the baseline) and decreased pulsatility index (PI; normal values 1–10) accompanied by acute increases in serum lactate dehydrogenase (≥2-fold above the baseline) and elevated plasma-free haemoglobin (>12 mg/dL) in the absence of other causes of haemolysis.[115]

In addition to clinical, haemodynamic, and laboratory parameters, echocardiography plays a pivotal role in recognizing PT (*Table 6*), starting from the evaluation of inflow and outflow cannula systolic velocities (Box *12*). Sometimes, LV contraction may attempt to increase to speed blood flow through the pump, resulting in an increased systolic cannula velocity, although this partially depends on the site of thrombus—inflow cannula velocities may be increased or reduced, while there can even be backflow (in pump stop).[6] Diastolic velocity, which is generated by the LVAD alone, decreases concomitantly in correlation with the degree of thrombus interference with pump function, suggesting impaired device contribution to flow. The ratio of systolic/diastolic flow velocity is therefore increased.[12]

Box 12 Long-term follow-up complication assessment of LVAD recipients

Serial echocardiographic assessment, if possible with a ramp test, is advisable in LVAD recipients to assess LV and RV function and loading over long-term follow-up. Ultrasound-enhancing agents (UEAs) may be used to help assess RV dimensions and function. Cardiac CT should be used in case of reduced LVAD flow.

Echocardiography is the first imaging modality to assess pump thrombosis. Systolic and diastolic velocities of inflow cannula should always be assessed. Ramp testing and cardiac CT should be used for their additional diagnostic value.

AR quantification by echocardiography at different pump speeds is advisable in all LVAD recipients. Due to challenging apical views, not all the parameters are available. Vena contracta >6 mm and AR jet height/LVOT >30% are usually assessable. In continuous-flow LVAD, peak systolic-to-diastolic velocity ratio of the outflow graft and diastolic acceleration of the outflow graft could be used for AR quantification.

TTE may be limited by acoustic shadowing on TTE for the assessment of LVAD mechanical complications (e.g. cannula mal-positioning), and sometimes TOE may be required for inflow/outflow cannula interrogation. CT angiography or ventriculography should be applied when TTE/TOE do not offer sufficient information.

Echocardiography is the first imaging modality to assess LVAD infections; however, 18F-FDG PET/CT is the most sensitive tool to investigate infection localization and extension and provides prognostic information. In doubtful cases, WBC SPECT/CT could be used as more specific.

Table 6 LVAD alarm troubleshooting by echocardiography

Reduced LVAD flow Echocardiographic finding	Diagnosis
RV dilatation	Right heart failure
Reduced TAPSE and tissue Doppler velocity	
Atrial/ventricular septal shift to left	
Increase and triangular early peaking tricuspid regurgitation jet	
IVC dilatation and reduced/reversed hepatic venous flow pattern	
Pericardial effusion	Tamponade
Right heart chamber collapse	
IVC dilatation and abnormal hepatic venous flow	
Reduced LV size	Hypovolemia
No features of right heart failure	Arrhythmia
Inadequate LV unloading: • Elevated filling pressure • Increased LV size • Recurrence of mitral regurgitation	Inflow/outflow graft obstruction
Increased LV ejection[a]	
Increased outflow graft flow velocity and turbulence	
Inadequate LV unloading: • Elevated filling pressure • Increased LV size • Recurrence of mitral regurgitation	Hypertension Inappropriately low pump speed
Increased LV ejection[a]	
Normal or increased LVAD flow Echocardiographic finding	**Diagnosis**
Aortic regurgitation	Aortic regurgitation
Increased LV size	
Recurrence of MR	
Elevated filling pressure	
Increased LVAD flow	Vasodilatation (e.g. sepsis, vasodilators)
Reduced pulsatility in flow (outflow graft Doppler)	
No change or reduced LV size	

MR, mitral regurgitation; LV, left ventricle; LVAD, left ventricular assist device; TAPSE, tricuspid annular plane systolic excursion.
[a]Increase in LV ejection dependent on LV contractile function and pump setting.

A too frequent and wide AV opening may indicate a sub-optimal LVAD speed or pump dysfunction,[116] although opening of the AV reduces the risk of thrombus formation. Spontaneous opening of the AV V is particularly important when the outflow graft is located in the descending aorta (e.g. in Jarvik 2000) as the AV is not washed by the blood flow. Aortic root thrombosis can also occur in patients with CF-LVADs.

Finally, the ramp test may be helpful in aiding in the diagnosis of PT.[117]

The presence of PI slope in the lower quartile, AV closure at higher speed, LVEDD flat slope, and a dramatically high-power slope are suggestive of device thrombosis.

As a future perspective, a protocol for ramp testing should become widely established and validated. Cardiac CT can also be used to evaluate LVAD thrombosis, which appears as low-attenuating material that creates a focal filling defect. Contrarily, normal CT appearance of the pump can be seen as circumferential, hypoattenuating material with variable thickness around the outflow cannula.[67]

Aortic regurgitation

Late aortic regurgitation may develop in up to the 30% of patients in the first year after LVAD implantation,[118] reducing pump efficiency mostly due to inadequate LV unloading and peripheral hypoperfusion. LVAD settings should allow a residual AV opening that can be constant, at every cardiac cycle, or at least intermittent (for example during low intermittent speed in CF-LVAD).[119] M-mode or B-mode at AV should include the registration of five to seven cardiac cycles to investigate cusps' excursion. Significant aortic regurgitation can be defined as at least moderate regurgitation.[120] Echocardiographic assessment can be technically challenging in apical views so it should rely mostly on the parasternal long-axis view. First, aortic regurgitation duration is a key point: a continuous vs. diastolic regurgitation (more common in CF-LVAD) is usually more severe and consequently correlated with a worse outcome in terms of symptoms, hospitalization, and survival.[121] The aortic jet 'vena contracta' width, with a cut-off >6 mm, denotes severe regurgitation. AR jet height/LVOT diameter ratio might represent another useful parameter (being >30% indicative for relevant AR). On the contrary, pressure half-time and effective regurgitant orifice area are usually not assessable. Aortic root dimensions and LVEDD and LVESD must be included in each echocardiographic report. To improve aortic regurgitation quantification in CF-LVADs, two recent parameters have been proposed: peak systolic-to-diastolic velocity ratio of the outflow graft (with values of <5.0 indicating at least moderate aortic regurgitation) and diastolic acceleration of the outflow graft (significant aortic regurgitation for acceleration >49 cm/s).[122,123] Aortic regurgitation assessment should be repeated with different LVAD pump speeds, although speed reduction should be avoided in cases of suspected or known aortic root thrombosis in order to prevent cusp opening and possible embolization (Box *12*).

Mechanical complications (inflow/outflow cannula malpositioning/kinking, graft twisting, and driveline issues)

One of the dreaded complications of LVAD implantation is mechanical obstruction of the device, which may be secondary to PT, as discussed in the previous paragraph, or to mechanical obstruction. Obstruction of a cannula is a cause of low device flow and, in some instances, is due to improperly positioned cannula or kinking or twisting of the outflow graft.[124]

The inflow cannula should be aligned with the mitral valve opening and should not have any contact with the LV walls. Misalignment can lead to obstruction of the inflow cannula at rest and with activities and can provoke clinical symptoms. Turbulent flow with elevated velocities via continuous-wave Doppler should raise a suspicion of cannula obstruction.[5] The normal filling velocity is between 1 and 2 m/s, depending on the preload and the intrinsic LV function. The outflow graft anastomosis to the ascending aorta can be visualized approximately at the level of the right pulmonary artery.[19] Evidence of high velocities (>2.0 m/s) can be indicative of obstruction of the outflow graft.[6] The angle of insertion of the LVAD outflow graft into the native aorta can influence flow patterns and velocities. Placing the outflow graft at a shallower angle can improve forward blood flow and reduce turbulence.[125] In a similar way, mal-angulation of the inflow cannula away from the LV apical axis leads to markedly unfavourable haemodynamics within the LV, impairs effective unloading, and thus significantly



Figure 8 Example of FDG PET/CT scan from a patient with LVAD infection. Modified with permission from Akin *et al.*[134] (*A*) Case AI: 18F-FDG PET/CT images of a high FDG ring around the inflow cannula of the LVAD. Banded ring (indicated by arrows) with high degree of accumulation in the connection part of the inflow cannula with the housing. (*B*) Case AI: picture of the debris we found in the connection between inflow cannula and pump housing (hands of Dr A.P.W.M. Maat). 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; LVAD, left ventricular assist device.

diminishes the overall benefit of device support.[126] Moreover, this strongly impacts platelet activation and increases risk of thrombosis.[104] The outflow graft may also be subject to external obstruction; in this case, early diagnosis is fundamental.[127]

Acoustic shadowing on TTE may limit Doppler interrogation of the inflow and outflow cannulae, and sometimes, TOE is required to obtain valid, reliable velocities; when echocardiography is not sufficient to make the diagnosis, patients may need to undergo CT angiography or ventriculography (Box *12*).

Outflow graft twisting is a rare complication, as demonstrated in the 2-year experience of the MOMENTUM 3 trial,[83] and represents a slowly progressive condition, leading to a drop of the pump flow without



Figure 9 Diagnostic flow chart of a patient with suspected LVAD infection. Modified with permission from Dilsizian *et al.*[135] FDG PET/CT, fluorodeoxyglucose positron emission tomography/computed tomography; TEE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC, white blood cell.

signs of PT. When low flows are encountered, and obvious causes excluded, the diagnostic approach should immediately focus on detection of a potential outflow graft obstruction. This should typically include a chest radiography, to look for a change in pump position over time to detect pump migration or re-orientation, and an echocardiogram, to exclude alternate causes of low-flow states. Finally, the confirmation of the diagnosis requires the use of contrast imaging, best done with CT angiography and conventional angiography.[128,129]

Damage to the driveline that interferes with the operation of the pump is a rare, but life-threatening complication. It is often caused by fracture due to accidental mechanical impact but intentional cutting or disconnection of the driveline from the controller has also been described. The most typical clinical findings associated with driveline failure are the red heart alarm and a drop in the pump speed below the auto-speed–low set limit. Radiography showing driveline kinking or fraying in patients with unexplained alterations in LVAD performance suggests driveline damage and requires surgical management.[130,131]

Infections

Late LVAD infection is an important, challenging, and potentially serious complication following LVAD implantation, which is associated with high morbidity and mortality and might require pump exchange. Infection rates in the EUROMACS Registry were higher in the early period (<3 months) compared to the late period (1.44 vs. 0.45 events/person-year).[112] While in the INTERMACS Registry, half of LVAD patients developed infection, which was associated with excess mortality. The 2-year unadjusted all-cause mortality of LVAD recipients with infection was 41.0% compared with 25.2% for those without infection.[132]

Nuclear imaging relies on the fact that infection stimulates neutrophils and other inflammatory cells with high metabolic requirements around the site of infection creating 'hot spots'. These cells are characterized by high level of glucose utilization and so they also demonstrate avid uptake of the glucose analogue and radiotracer 18F-FDG. The process of immune cell migration takes place early during infection, which makes 18F-FDG PET/CT a very sensitive tool to early detect infection, although careful differentiation from physiological uptake of 18F-FDG by the myocardium (glucose is a major energy source for myocytes) and careful dietary preparation to minimize this is required. The use of 18F-FDG PET/CT in the assessment of cardiac infection has been recognized in the 2015 infective endocarditis guidelines[133] (*Figure 8*). Several studies have demonstrated that FDG PET/CT can accurately localize the site and extent of the late LVAD infection across the peripheral driveline and the involvement of the central portion of the pump.[134] Furthermore, it predicts clinical outcomes of patients with

LVAD infection better than CT.[83] Tam *et al.* reported a pooled sensitivity of 92% and specificity of 83% for FDG PET/CT in the diagnosis of LVAD infections (Box *12*).

In cases of a non-diagnostic echo and PET/CT in patients with suspected LVAD infection (*Figure 9*), radiolabelled white blood cell scintigraphy [WBC single-photon emission computer tomography (SPECT)/CT] can be used to assess LVAD infection. Overall, this technique is less sensitive but more specific than FDG PET/CT to detect LVAD infections. While it involves a much more complicated imaging protocol and local expertise, WBC SPECT/CT can also help differentiate infection from inflammation, particularly in patients with equivocal FDG PET/CT.[135–137]

Conclusions

Survival in patients with advanced HF has improved significantly over the last two decades with LVAD therapy. However, patients with LVADs are burdened with troublesome and sometimes life-limiting complications. Multimodality cardiac imaging is fundamental for the pre-operative evaluation of LVAD candidates, the peri-operative evaluation of LVAD recipients, and post-operative assessment of short- and long-term complications in patients with long-term LVADs (*Graphical Abstract*). In this EACVI clinical consensus statement, the role of each imaging modality in the possible clinical scenarios of LVAD implantation, with advantages and caveats, is explored, highlighting the need for close integration of the different imaging modalities to optimize the management of patients with LVADs.

Acknowledgements

The authors would like to thank Sakir Akin [Department of Cardiology, Unit Heart Failure, Heart Transplantation & Mechanical Circulatory Support, Erasmus Microcirculation (MC) University Medical Center Rotterdam, Rotterdam, The Netherlands], Francesca Baessato (Department of Cardiology, Regional Hospital S. Maurizio, Bolzano, Italy), Francesca Maria Righini (Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy), and Federico Landra (Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy) for critically reviewing the paper.

Conflict of interest: E.D.: research and teaching facilities from General Electric Healthcare and Abbott structural. M.Ci.: investigator-initiated research grants to institution: Novartis and Abbott; advisory role, speaker honoraria, and travel grants: Abbott, Abiomed, and GE Healthcare. All other authors have no conflict of interest to declare related to this paper.

Data availability

No new data were generated or analysed in support of this research.

References

1. Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I *et al.* The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. *Eur J Heart Fail.* 2021;**23**:906–14.
2. Hariri IM, Dardas T, Kanwar M, Cogswell R, Gosev I, Molina E *et al.* Long-term survival on LVAD support: device complications and end-organ dysfunction limit long-term success. *J Heart Lung Transplant* 2022;**41**:161–70.
3. Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. *Eur J Heart Fail* 2017;**19**:595–602.
4. Todaro MC, Khandheria BK, Paterick TE, Umland MM, Thohan V. The practical role of echocardiography in selection, implantation, and management of patients requiring LVAD therapy. *Curr Cardiol Rep* 2014;**16**:468.
5. Ammar KA, Umland MM, Kramer C, Sulemanjee N, Jan MF, Khandheria BK *et al.* The ABCs of left ventricular assist device echocardiography: a systematic approach. *Eur Heart J Cardiovasc Imaging* 2012;**13**:885–99.
6. Stainback RF, Estep JD, Agler DA, Birks EJ, Bremer M, Hung J *et al.* Echocardiography in the management of patients with left ventricular assist devices: recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr* 2015;**28**:853–909.
7. Almarzooq ZI, Varshney AS, Vaduganathan M, Pareek M, Stewart GC, Estep JD *et al.* Expanding the scope of multimodality imaging in durable mechanical circulatory support. *JACC Cardiovasc Imaging* 2020;**13**:1069–81.
8. Mehra MR, Uriel NY, Cleveland NJC Jr, Yuzefpolskaya M, Salerno CT, Wlash MN, *et al.* A fully magnetically levitated left ventricular assist device—final report. *N Eng J Med* 2019;**380**:1618–27.
9. Sciaccaluga C, Soliman-Aboumarie H, Sisti N, Mandoli GE, Cameli P, Bigio E *et al.* Echocardiography for left ventricular assist device implantation and evaluation: an indispensable tool. *Heart Fail Rev* 2022;**27**:891–902.
10. Patel SR, Saeed O, Naftel D, Myers S, Kirklin J, Jorde UP *et al.* Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis. *J Card Fail* 2017;**23**:859–67.
11. Soliman OII, Akin S, Muslem R, Boersma E, Manintveld OC, Krabatsch T *et al.* Derivation and validation of a novel right-sided heart failure model after implantation of continuous flow left ventricular assist devices: the EUROMACS (European Registry for patients with mechanical circulatory support) right-sided heart failure risk score. *Circulation* 2018;**137**:891–906.
12. Jones N, Burns AT, Prior DL. Echocardiographic assessment of the right ventricle—state of the art. *Heart Lung Circ* 2019;**28**:1339–50.
13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L *et al.* Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015;**16**:233–70.
14. Nadziakiewicz P, Niklewski T, Szygula-Jurkiewicz B, Pacholewicz J, Zakliczynski M, Przybylowski P *et al.* Left ventricular assist device implantation in patients with optimal and borderline echocardiographic assessment of right ventricle function. *Transplant Proc* 2018;**50**:2080–4.
15. Chriqui LE, Monney P, Kirsch M, Tozzi P. Prediction of right ventricular failure after left ventricular assist device implantation in patients with heart failure: a meta-analysis comparing echocardiographic parameters. *Interact Cardiovasc Thorac Surg* 2021;**33**:784–92.
16. Liang LW, Jamil A, Mazurek JA, Urgo KA, Wald J, Birati EY *et al.* Right ventricular global longitudinal strain as a predictor of acute and early right heart failure post left ventricular assist device implantation. *ASAIO J* 2022;**68**:333–9.
17. Isaza N, Gonzalez M, Saijo Y, Vega Brizneda M, Estep J, Starling RC *et al.* Incremental value of global longitudinal strain to Michigan risk score and pulmonary artery pulsatility index in predicting right ventricular failure following left ventricular assist devices. *Heart Lung Circ* 2022;**31**:1110–8.
18. Katapadi A, Umland M, Khandheria BK. Update on the practical role of echocardiography in selection, implantation, and management of patients requiring left ventricular assist device therapy. *Curr Cardiol Rep* 2022;**24**:1587–97.
19. Flores AS, Essandoh M, Yerington GC, Bhatt AM, Iyer MH, Perez W *et al.* Echocardiographic assessment for ventricular assist device placement. *J Thorac Dis* 2015;**7**:2139–50.
20. Bowen DJ, Yalcin YC, Strachinaru M, McGhie JS, van den Bosch AE, Soliman OI *et al.* Right ventricular functional assessment by 2D multi-plane echocardiography prior to left ventricular assist device implantation. *Echocardiography* 2022;**39**:7–19.
21. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R *et al.* Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *J Am Soc Echocardiogr* 2015;**28**:183–93.
22. Sugimoto T, Dulgheru R, Bernard A, Ilardi F, Contu L, Addetia K *et al.* Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study. *Eur Heart J Cardiovasc Imaging* 2017;**18**:833–40.
23. Muraru D, Haugaa K, Donal E, Stankovic I, Voigt JU, Petersen SE *et al.* Right ventricular longitudinal strain in the clinical routine: a state-of-the-art review. *Eur Heart J Cardiovasc Imaging* 2022;**23**:898–912.
24. Tamborini G, Muratori M, Brusoni D, Celeste F, Maffessanti F, Caiani EG *et al.* Is right ventricular systolic function reduced after cardiac surgery? A two- and three-dimensional echocardiographic study. *Eur J Echocardiogr* 2009;**10**:630–4.
25. Barssoum K, Altibi AM, Rai D, Kharsa A, Kumar A, Chowdhury M *et al.* Assessment of right ventricular function following left ventricular assist device (LVAD) implantation—the role of speckle-tracking echocardiography: a meta-analysis. *Echocardiography* 2020;**37**:2048–60.
26. Motoki H, Borowski AG, Shrestha K, Hu B, Kusunose K, Troughton RW *et al.* Right ventricular global longitudinal strain provides prognostic value incremental to left ventricular ejection fraction in patients with heart failure. *J Am Soc Echocardiogr* 2014;**27**:726–32.
27. Guendouz S, Rappeneau S, Nahum J, Dubois-Randé JL, Gueret P, Monin JL *et al.* Prognostic significance and normal values of 2D strain to assess right ventricular systolic function in chronic heart failure. *Circ J* 2012;**76**:127–36.
28. Cameli M, Lisi M, Righini FM, Tsioulpas C, Bernazzali S, Maccherini M *et al.* Right ventricular longitudinal strain correlates well with right ventricular stroke work index in

patients with advanced heart failure referred for heart transplantation. *J Card Fail* 2012; **18**:208–15.
29. Lisi M, Cameli M, Righini FM, Malandrino A, Tacchini D, Focardi M *et al.* RV longitudinal deformation correlates with myocardial fibrosis in patients with end-stage heart failure. *JACC Cardiovasc Imaging* 2015;**8**:514–22.
30. Gumus F, Sarıcaoglu C, Inan MB, Akar AR. Right ventricular strain to assess early right heart failure in the left ventricular assist device candidate. *Curr Heart Fail Rep* 2019;**16**: 212–9.
31. Bellavia D, Iacovoni A, Scardulla C, Moja L, Pilato M, Kushwaha SS *et al.* Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. *Eur J Heart Fail* 2017;**19**:926–46.
32. Cameli M, Pastore MC, Mandoli GE, Nistor D, Lisi E, Tok ÖÖ *et al.* Prognosis and risk stratification of patients with advanced heart failure (from PROBE). *Am J Cardiol* 2019; **124**:55–62.
33. Stricagnoli M, Sciaccaluga C, Mandoli GE, Rizzo L, Sisti N, Aboumarie HS *et al.* Clinical, echocardiographic and hemodynamic predictors of right heart failure after LVAD placement. *Int J Cardiovasc Imaging* 2022;**38**:561–70.
34. Ahmad A, Li H, Zhang Y, Liu J, Gao Y, Qian M *et al.* Three-dimensional echocardiography assessment of right ventricular volumes and function: technological perspective and clinical application. *Diagnostics (Basel)* 2022;**12**:806.
35. Muraru D. 22nd Annual Feigenbaum Lecture: right heart, right now: the role of three-dimensional echocardiography. *J Am Soc Echocardiogr* 2022;**35**:893–909.
36. Muraru D, Spadotto V, Cecchetto A, Romeo G, Aruta P, Ermacora D *et al.* New speckle-tracking algorithm for right ventricular volume analysis from three-dimensional echocardiographic data sets: validation with cardiac magnetic resonance and comparison with the previous analysis tool. *Eur Heart J Cardiovasc Imaging* 2016; **17**:1279–89.
37. Muraru D, Cecchetto A, Cucchini U, Zhou X, Lang RM, Romeo G *et al.* Intervendor consistency and accuracy of left ventricular volume measurements using three-dimensional echocardiography. *J Am Soc Echocardiogr* 2018;**31**:158–168.e1.
38. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. *J Am Coll Cardiol* 2013;**61**:77–84.
39. Otten A, Kurz S, Anwar S, Potapov E, Krall C, O'Brien B *et al.* Prognostic value of 3-dimensional echocardiographical heart volume assessment in patients scheduled for left ventricular assist device implantation. *Eur J Cardiothorac Surg* 2018;**54**:169–75.
40. Addetia K, Uriel N, Maffessanti F, Sayer G, Adatya S, Kim GH *et al.* 3D morphological changes in LV and RV during LVAD ramp studies. *JACC Cardiovasc Imaging* 2018;**11** (2 Pt 1):159–69.
41. Kiernan MS, French AL, DeNofrio D, Parmar YJ, Pham DT, Kapur NK *et al.* Preoperative three-dimensional echocardiography to assess risk of right ventricular failure after left ventricular assist device surgery. *J Card Fail* 2015;**21**:189–97.
42. Magunia H, Dietrich C, Langer HF, Schibilsky D, Schlensak C, Rosenberger P *et al.* 3D echocardiography derived right ventricular function is associated with right ventricular failure and mid-term survival after left ventricular assist device implantation. *Int J Cardiol* 2018;**272**:348–55.
43. Sayer G, Medvedofsky D, Imamura T, Kim G, Maffessanti F, Fried J *et al.* Short-term ventricular structural changes following left ventricular assist device implantation. *ASAIO J* 2021;**67**:169–76.
44. Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R *et al.* Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper. *Eur Heart J Cardiovasc Imaging* 2022;**23**:e171–232.
45. Yastrebov K, Brunel L, Paterson HS, Williams ZA, Wise IK, Burrows CS *et al.* Intracardiac echocardiography for point-of-care guided left ventricular assist device implantation: surgical implications for COVID-19. *Surg Innov* 2022;**29**:292–4.
46. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. *J Cardiovasc Magn Reson* 2020;**22**:17.
47. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M *et al.* 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail.* 2022;**24**:4–131.
48. Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalani A, Dorian P *et al.* Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. *J Cardiovasc Magn Reson* 2012;**14**: 69.
49. Writing Committee Members; Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK *et al.* 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *J Am Coll Cardiol* 2021;**78**:e187–285.
50. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O *et al.* Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. *Circulation* 1999;**100**:1992–2002.
51. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O *et al.* The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med* 2000;**343**:1445–53.
52. Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. *JACC Cardiovasc Imaging* 2012;**5**:494–508.
53. Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. cardiac magnetic resonance imaging for the diagnosis of left ventricular thrombus: a systematic review. *Can J Cardiol* 2015;**31**:785–91.
54. Wang G, Lee SE, Yang Q, Sadras V, Patel S, Yang HJ *et al.* Multicenter study on the diagnostic performance of native-T1 cardiac magnetic resonance of chronic myocardial infarctions at 3 T. *Circ Cardiovasc Imaging* 2020;**13**:e009894. Epub 2020 Jun 8. Erratum in: Circ Cardiovasc Imaging. 2021 Aug;14(8):e000073. PMID: 32507020; PMCID: PMC 7363195.
55. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ *et al.* 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J.* 2017;**38**:2739–91.
56. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H *et al.* 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC). *Eur Heart J.* 2014;**35**:2873–926. Epub 2014 Aug 29. Erratum in: Eur Heart J. 2015 Nov 1;36(41):2779. PMID: 25173340.
57. Shanmuganathan M, Rajani P, Androulakis E, Moledina S, Sarri G, Robertus J *et al.* Predicting significant right ventricular failure post-LVAD implantation using CMR compared to echocardiography and right heart catheterisation. *J Heart Lung Transplant*, 2021;**40**:S438.
58. Raman SV, Tran T, Simonetti OP, Sun B. Dynamic computed tomography to determine cardiac output in patients with left ventricular assist devices. *J Thorac Cardiovasc Surg* 2009;**137**:1213–7.
59. Barac YD, Ben-Avraham B, Hamdan A, Hirsch R, Ben-Gal T, Aravot D. Heartmate 3 as a bridge to heart transplantation in a patient with congenitally corrected transposition of the great arteries: a case report. *J Cardiothorac Surg* 2022;**17**:54.
60. Stepanenko A, Potapov EV, Weng Y, Pasic M, Krabatsch T, Hetzer R. Concomitant surgery during ventricular assist device implantation. *Ann Cardiothorac Surg* 2014;**3**: 630–1.
61. Morgan JA, Tsiouris A, Nemeh HW, Hodari A, Karam J, Brewer RJ *et al.* Impact of concomitant cardiac procedures performed during implantation of long-term left ventricular assist devices. *J Heart Lung Transplant* 2013;**32**:1255–61.
62. Anselmi A, Collin S, Haigron P, Verhoye JP, Flecher E. Virtual implantation of a novel LVAD: toward computer-assisted surgery for heart failure. *J Surg Res* 2016;**205**:204–7.
63. Funabashi N, Maeda F, Nakamura K, Suzuki K, Mita Y, Matsuo K *et al.* Channel-like appearance of a patent foramen ovale with left to right shunt demonstrated by 64-slice computed tomography. *Int J Cardiol* 2007;**119**:119–21.
64. Lee S, Kim IC, Kim YD, Nam HS, Kim SY, Choi SM *et al.* The role of cardiac CT throughout the full cardiac cycle in diagnosing patent foramen ovale in patients with acute stroke. *Eur Radiol* 2021;**31**:8983–90.
65. Ohta Y, Kitao S, Yunaga H, Fujii S, Mukai N, Yamamoto K *et al.* Myocardial delayed enhancement CT for the evaluation of heart failure: comparison to MRI. *Radiology* 2018; **288**:682–91.
66. Flachskampf FA, Wouters PF, Edvardsen T, Evangelista A, Habib G, Hoffman P *et al.* Recommendations for transoesophageal echocardiography: EACVI update 2014. *Eur Heart J Cardiovasc Imaging.* 2014;**15**:353–65.
67. Schmitto JD, Krabatsch T, Damme L, Netuka I. Less invasive HeartMate 3 left ventricular assist device implantation. *J Thorac Dis* 2018;**10**(Suppl 15):S1692–5.
68. Melehy A', O'Connell G, Ning Y, Kurlansky P, Kaku Y, Topkara V *et al.* Role of left atrial appendage occlusion in patients with HeartMate 3. *Interact Cardiovasc Thorac Surg.* 2022;**34**:668–75.
69. Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B *et al.* American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. *J Am Soc Echocardiogr* 2013;**26**:965–1012.e15.
70. Faehnrich JA, Noone RB, White WD, Leone BJ, Hilton AK, Sreeram GM *et al.* Effects of positive pressure ventilation, pericardial effusion and cardiac tamponade on respiratory variation in transmitral flow velocities. *J Cardiothorac Vasc Anesth* 2003;**17**:45–50.
71. Leimgruber PP, Klopfenstein HS, Wann LS, Brooks HL. The hemodynamic derangement associated with right ventricular diastolic collapse in cardiac tamponade: an experimental echocardiographic study. *Circulation* 1983;**68**:612–20.
72. Morgan JA, Kormos RL, Long JW, Slaughter MS. Discussions in cardiothoracic treatment and care: mechanical circulatory support left ventricular assist device therapy for patients with advanced heart failure. *Semin Thorac Cardiovasc Surg* 2018;**30**:42–9.

73. Meineri M, Van Rensburg AE, Vegas A. Right ventricular failure after LVAD implantation: prevention and treatment. *Best Pract Res Clin Anaesthesiol* 2012;**26**:217–29.
74. Argiriou M, Kolokotron SM, Sakellaridis T, Argiriou O, Charitos C, Zarogoulidis P *et al.* Right heart failure post left ventricular assist device implantation. *J Thorac Dis* 2014; **6**(Suppl 1):S52–9.
75. Jonathan Neyer MD, Reza Arsanjani MD, Jaime Moriguchi MD, Robert Siegel MD, Jon Kobashigawa MD. Echocardiographic parameters associated with right ventricular failure after left ventricular assist device: a review. *J Heart Lung Transplant* 2016;**35**: 283–93.
76. Li X, Kondray V, Tavri S, Ruhparwar A, Azeze S, Dey A *et al.* Role of imaging in diagnosis and management of left ventricular assist device complications. *Int J Cardiovasc Imaging* 2019;**35**:1365–77.
77. Frazier OH, Myers TJ, Jarvik RK, Westaby S, Pigott DW, Gregoric ID. Research and development of an implantable, axial-flow left ventricular assist device: the Jarvik 2000 Heart. *Ann Thorac Surg* 2001;**71**(3 Suppl):S125–32; discussion S144–6.
78. Maniar S, Kondareddy S, Topkara VK. Left ventricular assist device-related infections: past, present and future. *Expert Rev Med Devices* 2011;**8**:627–34.
79. Topkara VK, Kondareddy S, Malik F, Wang IW, Mann DL, Ewald GA *et al.* Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. *Ann Thorac Surg* 2010;**90**:1270–7.
80. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M *et al.* Recommendations for the practice of echocardiography in infective endocarditis. *Eur J Echocardiogr* 2010;**11**:202–19.
81. Vilacosta I, Sarriá C, San Román JA, Jiménez J, Castillo JA, Iturralde E *et al.* Usefulness of transesophageal echocardiography for diagnosis of infected transvenous permanent pacemakers. *Circulation* 1994;**89**:2684–7.
82. Dell'Aquila AM, Mastrobuoni S, Alles S, Wenning C, Henryk W, Schneider SR *et al.* Contributory role of fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis and clinical management of infections in patients supported with a continuous-flow left ventricular assist device. *Ann Thorac Surg* 2016;**101**:87–94; discussion 94.
83. Tam MC, Patel VN, Weinberg RL, Hulten EA, Aaronson KD, Pagani FD *et al.* Diagnostic accuracy of FDG PET/CT in suspected LVAD infections: a case series, systematic review, and meta-analysis. *JACC Cardiovasc Imaging* 2020;**13**:1191–202.
84. de Vaugelade C, Mesguich C, Nubret K, Camou F, Greib C, Dournes G *et al.* Infections in patients using ventricular-assist devices: comparison of the diagnostic performance of ^{18}F-FDG PET/CT scan and leucocyte-labeled scintigraphy. *J Nucl Cardiol* 2019;**26**: 42–55.
85. Kim J, Feller ED, Chen W, Liang Y, Dilsizian V. FDG PET/CT for early detection and localization of left ventricular assist device infection: impact on patient management and outcome. *JACC Cardiovasc Imaging* 2019;**12**:722–9.
86. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM *et al.* 2019 EACTS expert consensus on long-term mechanical circulatory support. *Eur J Cardiothorac Surg* 2019;**56**:230–70.
87. Zoghbi WA, Asch FM, Bruce C, Gillam LD, Grayburn PA, Han RT *et al.* Guidelines for the evaluation of valvular regurgitation after percutaneous valve repair or replacement. A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr* 2019;**32**:431–75.
88. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT *et al.* Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA* 2022;**328**:1233–42.
89. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. *J Cardiovasc Transl Res* 2010;**3**:618–24.
90. Jain A, Rohrer B, Gebhardt B, Breeze JL, Quick JD, Couper G *et al.* Left ventricular assist device thrombosis is associated with an increase in the systolic-to-diastolic velocity ratio measured at the inflow and outflow cannulae. *J Cardiothorac Vasc Anesth* 2017;**31**: 497–504.
91. Goldstein DJ, John R, Salerno C, Silvestry S, Moazami N, Horstmanshof D *et al.* Algorithm for the diagnosis and management of suspected pump thrombus. *J Heart Lung Transplant* 2013;**32**:667–70.
92. Mohamed I, Lau CT, Bolen MA, El-Sherief AH, Azok JT, Karimov JH *et al.* Building a bridge to save a failing ventricle: radiologic evaluation of short- and long-term cardiac assist devices. *Radiographics* 2015;**35**:327–56.
93. Sacks J, Gonzalez-Stawinski GV, Hall S, Lima B, MacHannaford J, Dockery W *et al.* Utility of cardiac computed tomography for inflow cannula patency assessment and prediction of clinical outcome in patients with the HeartMate II left ventricular assist device. *Interact Cardiovasc Thorac Surg* 2015;**21**:590–3.
94. Yanagisawa R, Hayashida K, Yamada Y, Tanaka M, Yashima F, Inohara T *et al.* Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. *JACC Cardiovasc Imaging* 2016.
95. Imamura T, Chung B, Nguyen A, Sayer G, Uriel N. Clinical implications of hemodynamic assessment during left ventricular assist device therapy. *J Cardiol* 2018;**71**:352–8.
96. Estep JD, Stainback RF, Little SH, Torre G, Zoghbi WA. The role of echocardiography and other imaging modalities in patients with left ventricular assist devices. *JACC Cardiovasc Imaging* 2010;**3**:1049–64.
97. Tatli S, Lipton MJ. CT for intracardiac thrombi and tumors. *Int J Cardiovasc Imaging* 2005;**21**:115–31.
98. Neidlin M, Liao S, Li Z, Simpson B, Kaye DM, Steinseifer U *et al.* Understanding the influence of left ventricular assist device inflow cannula alignment and the risk of intraventricular thrombosis. *Biomed Eng Online* 2021;**20**:47.
99. Ghodrati M, Maurer A, Schlöglhofer T, Khienwad T, Zimpfer D, Beitzke D *et al.* The influence of left ventricular assist device inflow cannula position on thrombosis risk. *Artif Organs* 2020;**44**:939–46.
100. Chivukula VK, Beckman JA, Li S, Masri SC, Levy WC, Lin S *et al.* Left ventricular assist device inflow cannula insertion depth influences thrombosis risk. *ASAIO J* 2020;**66**: 766–73.
101. Trankle CR, Grizzard JD, Shah KB, Rezai Gharai L, Dana F, Kang MS *et al.* Left ventricular assist device outflow graft compression: incidence, clinical associations and potential etiologies. *J Card Fail* 2019;**25**:545–52.
102. Jain SS, Clerkin KJ, Anstey DE, Liu Q, Fried JA, Raikhelkar J *et al.* Outflow graft narrowing of the HeartMate 3 left ventricular assist device. *Ann Thorac Surg* 2023;**115**:1282–8.
103. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD *et al.* Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med* 2007;**357**:885–96.
104. Chivukula VK, Beckman JA, Prisco AR, Dardas T, Lin S, Smith JW *et al.* Left ventricular assist device inflow cannula angle and thrombosis risk. *Circ Heart Fail* 2018;**11**:e004325.
105. Antonides CFJ, Schoenrath F, de By T, Muslem R, Veen K, Yalcin YC *et al.* Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study. *ESC Heart Fail* 2020;**7**:1085–94.
106. Birks EJ, Drakos SG, Patel SR, Lowes BD, Selzman CH, Starling RC *et al.* Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [remission from stage D heart failure]): medium-term and primary end point results. *Circulation* 2020;**142**:2016–28.
107. Monteagudo Vela M, Rial Bastón V, Panoulas V, Riesgo Gil F, Simon A. A detailed explantation assessment protocol for patients with left ventricular assist devices with myocardial recovery. *Interact Cardiovasc Thorac Surg* 2021;**32**:298–305.
108. Mirza A, Romero CM, Toyoda Y, Hamad EA. Identifying patients with a higher potential for recovery post left ventricular assist device: a single-center experience. *Ochsner J* 2021;**21**:341–6.
109. Mulzer J, Krastev H, Hoermandinger C, Merke N, Alhaloush M, Schoenrath F *et al.* Cardiac remodeling in patients with centrifugal left ventricular assist devices assessed by serial echocardiography. *Echocardiography* 2022;**39**:667–77.
110. Dandel M, Javier M, Javier Delmo EM, Loebe M, Hetzer R. Weaning from ventricular assist device support after recovery from left ventricular failure with or without secondary right ventricular failure. *Cardiovasc Diagn Ther* 2021;**11**:226–42.
111. William J, Mak V, Leet A, Kaye DM, Nanayakkara S. Optimal mechanical unloading in left ventricular assist device recipients relates to progressive up-titration in pump speed. *J Am Soc Echocardiogr* 2020;**33**:583–93.
112. de By TMMH, Schoenrath F, Veen KM, Mohacsi P, Stein J, Alkhamees KMM *et al.* The European Registry for patients with mechanical circulatory support of the European Association for Cardio-Thoracic Surgery: third report. *Eur J Cardiothorac Surg* 2022; **62**:ezac032.
113. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Myers S, Acker MA *et al.* Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS Registry. *J Heart Lung Transplant* 2015;**34**:1515–26.
114. Uriel N, Morrison KA, Garan AR, Kato TS, Yuzefpolskaya M, Latif F *et al.* Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. *J Am Coll Cardiol* 2012;**60**:1764–75.
115. Fine NM, Topilsky Y, Oh JK, Hasin T, Kushwaha SS, Daly RC *et al.* Role of echocardiography in patients with intravascular hemolysis due to suspected continuous-flow LVAD thrombosis. *JACC Cardiovasc Imaging* 2013;**6**:1129–40.
116. Topilsky Y, Oh JK, Atchison FW, Shah DK, Bichara VM, Schirger JA *et al.* Echocardiographic findings in stable outpatients with properly functioning HeartMate II left ventricular assist devices. *J Am Soc Echocardiogr* 2011;**24**:157–69.
117. Uriel N, Sayer G, Addetia K, Fedson S, Kim GH, Rodgers D *et al.* Hemodynamic ramp tests in patients with left ventricular assist devices. *JACC Heart Fail* 2016;**4**:208–17.
118. Rame JE, Pagani FD, Kiernan MS, Oliveira GH, Birati EY, Atluri P *et al.* Evolution of late right heart failure with left ventricular assist devices and association with outcomes. *J Am Coll Cardiol* 2021;**78**:2294–308.
119. Bouabdallaoui N, El-Hamamsy I, Pham M, Giraldeau G, Parent MC, Carrier M *et al.* Aortic regurgitation in patients with a left ventricular assist device: a contemporary review. *J Heart Lung Transplant* 2018;**37**:1289–97.
120. da Rocha E Silva JG, Meyer AL, Eifert S, Garbade J, Mohr FW, Strueber M *et al.* Influence of aortic valve opening in patients with aortic insufficiency after left ventricular assist device implantation. *Eur J Cardiothorac Surg* 2016;**49**:784–7.

121. Truby LK, Garan AR, Givens RC, Wayda B, Takeda K, Yuzefpolskaya M *et al.* Aortic insufficiency during contemporary left ventricular assist device support: analysis of the INTERMACS Registry. *JACC Heart Fail* 2018;**6**:951–60.
122. Grinstein J, Kruse E, Sayer G, Fedson S, Kim GH, Sarswat N *et al.* Novel echocardiographic parameters of aortic insufficiency in continuous-flow left ventricular assist devices and clinical outcome. *J Heart Lung Transplant* 2016;**35**:976–85.
123. Grinstein J, Kruse E, Sayer G, Fedson S, Kim GH, Jorde UP *et al.* Accurate quantification methods for aortic insufficiency severity in patients with LVAD: role of diastolic flow acceleration and systolic-to-diastolic peak velocity ratio of outflow cannula. *JACC Cardiovasc Imaging* 2016;**9**:641–51.
124. Asawaeer M, Kadir S, Albulushi A. Left ventricular assist device outflow cannula obstruction. Importance of multimodality imaging. *J Am Coll Cardiol Case Rep* 2020;**2**: 1454–6.
125. May-Newman KD, Hillen BK, Sironda CS, Dembitsky W. Effect of LVAD outflow conduit insertion angle on flow through the native aorta. *J Med Eng Technol* 2004;**28**: 105–9.
126. Zijderhand CF, Knol WG, Budde RPJ, van der Heiden CW, Veen KM, Sjatskig J *et al.* Relapsing low-flow alarms due to suboptimal alignment of the left ventricular assist device inflow cannula. *Eur J Cardiothorac Surg* 2022;**62**:ezac415.
127. Wert L, Stewart GC, Mehra MR, Milwidsky A, Jorde UP, Goldstein DJ *et al.* A multicenter evaluation of external outflow graft obstruction with a fully magnetically levitated left ventricular assist device. *J Thorac Cardiovasc Surg* 2024;**167**:1322–1330.e6.
128. Mehra MR, Salerno C, Naka Y, Uriel N, Cleveland JC, Horstmanshof D *et al.* A tale of the twist in the outflow graft: an analysis from the MOMENTUM 3 trial. *J Heart Lung Transplant* 2018;**37**:1281–4.
129. Konukoğlu O, Mansuroğlu D, Yıldırım Ö, Bakshaliyev S, Sever K, Balkanay M. Outflow graft twisting of Heartmate III left ventricular-assisted device: a case report. *Turk Gogus Kalp Damar Cerrahisi Derg* 2019;**27**:568–71.
130. Morris MF, Staley LL, Arabia FA, DeValeria PA, Collins JM. Abdominal X-ray imaging for detection of left ventricular assist device driveline damage. *J Heart Lung Transplant* 2012; **31**:1313–5.
131. Sen A, Larson JS, Kashani KB, Libricz SL. Mechanical circulatory assist devices: a primer for critical care and emergency physicians. *Critical Care* 2016;**20**:153.
132. Hannan MM, Xie R, Cowger J, Schueler S, de By T, Dipchand AI *et al.* Epidemiology of infection in mechanical circulatory support: a global analysis from the ISHLT mechanically assisted circulatory support registry. *J Heart Lung Transplant* 2019;**38**: 364–73.
133. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F *et al.* 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015;**36**:3075–128.
134. Akin S, Muslem R, Constantinescu AA, Manintveld OC, Birim O, Brugts JJ *et al.* 18F-FDG PET/CT in the diagnosis and management of continuous flow left ventricular assist device infections: a case series and review of the literature. *ASAIO J* 2018;**64**: e11–9.
135. Dilsizian V, Budde RPJ, Chen W, Mankad SV, Lindner JR, Nieman K. Best practices for imaging cardiac device-related infections and endocarditis: a JACC: cardiovascular imaging expert panel statement. *JACC Cardiovasc Imaging* 2022;**15**:891–911.
136. Hyafil F, Rouzet F, Lepage L, Benali K, Raffoul R, Duval X *et al.* Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. *Eur Heart J Cardiovasc Imaging* 2013;**14**:586–94.
137. Calais J, Touati A, Grall N, Laouenan C, Benali K, Mahida B *et al.* Diagnostic impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and white blood cell SPECT/computed tomography in patients with suspected cardiac implantable electronic device chronic infection. *Circ Cardiovasc Imaging* 2019;**12**:e007188.